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ABSTRACT 
Background: Cervical cancer is globally the fourth most common cancer in women and 
has generally a good prognosis. Cervical cancer survivors report persistent changes in their 
sexual function, which result in considerable distress. The majority of new cases are 
diagnosed in young or middle-aged women. Consequently, a rising number of women are at 
risk for chronic side effects of the treatment. The aim of this thesis was to investigate the 
morphology of the vaginal wall and the expression of sex steroid receptors in cervical 
cancer survivors treated with radiotherapy. 
 
Methods: Via clinical examination the degree of vaginal atrophy, pelvic fibrosis and 
telangiectasia were estimated. We collected vaginal biopsies, which underwent 
morphometric analyses focused on elastin, collagen, epithelial structures, blood vessels and 
nerve fibers. Radiation dose at biopsy site was calculated and sex steroid hormone levels 
were analyzed. We also analyzed the expression and distribution of sex steroid hormone 
receptors by real-time PCR and immunohistochemistry (IHC). Additionally, a questionnaire 
designed to assess sexual function was filled out. 
 
Results: The survivors had marked morphological vaginal changes, most prominent in the 
survivors that had received the highest radiation dose at the biopsy site. Clinical findings of 
atrophy, pelvic fibrosis and shortened vagina were present in most cancer survivors. Signs 
of elastosis with thick aggregated elastin fibers were found throughout the connective 
tissue. High-density collagen (fibrosis) in the connective tissue was more common among 
the survivors, most prominent in survivors that had received external radiation. The vaginal 
epithelium volume was reduced despite no difference in serum estradiol between cancer 
survivors and controls. In biopsies from the vaginal wall, lower expression of estrogen 
receptor alpha (ERα) at both mRNA and protein levels was found. In the survivors with 
high radiation dose at biopsy site, the immunostaining of ERα and androgen receptor (AR) 
was lower in the epithelium and the stroma, compared to survivors with minimal radiation 
dose. The cervical cancer survivors reported more physical sexual symptoms. The highest 
relative risk was found for insufficient vaginal lubrication, vaginal inelasticity, reduced 
genital swelling when sexually aroused and for reduction of vaginal length. 
 
Conclusion: The vaginal wall is markedly changed in irradiated cervical cancer survivors. 
The connective tissue is remodeled with elastosis and radiotherapy-induced fibrosis, and 
the vaginal epithelium volume is reduced, compared to controls with similar levels of 
estradiol. Reduction in ERα and AR expression in the vaginal mucosa after radiotherapy 
may alter the responsiveness to hormonal treatment. The morphological changes in the 
vaginal wall correspond to the clinical findings of fibrosis and atrophy and can be one 
important explanation of the sexual dysfunction in the cervical cancer survivors. 
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1 INTRODUCTION 
 
In the Western countries, the incidence of cervical cancer is decreasing, but is still one of 
the most common cancers affecting young and middle-aged women [1]. Advances in 
treatment of radiotherapy and additional chemotherapy have resulted in improvement in 
survival rates. Consequently, a rising number of cervical cancer survivors are at risk for 
chronic side effects. After treatment of cervical cancer, sexual dysfunction is a major 
symptom that affects women negatively. Still, vaginal pathophysiological changes and the 
effects of radiotherapy on the vaginal wall have received little attention. 
 
The goal of cancer treatment is to cure with minimal morbidity. It is therefore of great 
importance not just to obtain tumor control, but also measuring morbidity after treatment to 
ensure the best possible quality of life for cancer survivors. 
1.1 THE VAGINA 
1.1.1 Anatomy  
 
The vagina is a tubular organ extending from the uterus to the vestibulum. The vagina is 
developed by a prenatal fusion of the Müllerian ducts starting in gestational week 6. The 
fusion line can be seen as a longitudinal fold, columnae rugarum on the anterior and posterior 
wall. The average length is about 8-10 cm [2]; the front wall is slightly shorter than the 
posterior wall. Normally the vagina is collapsed with the front wall against the back wall. 
During sexual stimulation, the shape is changed and the back wall is extended. From the 
columnae rugarum originate horizontal folds, rugae vaginalis, which gives the vagina its great 
elasticity, a condition important at sexual intercourse and during childbirth. The vaginal wall 
has the following layers - the mucosa facing the lumen, the tunica muscularis comprising an 
inner circle of smooth muscle surrounded by a thicker outer longitudinally muscle layer and 
the exterior adventitia, a layer of connective tissue. The outer layer is rich in blood vessels, 
nerves and lymph vessels and shares part of the adventitia with the surrounding structures [3]. 
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1.1.2 Blood supply 
 
The vagina is richly vascularized and supplied by the vaginal arteries, branches of the uterine 
artery, middle rectal artery and the internal pudendal artery, all branches of the internal iliac 
arteries. A plexus of the vaginal veins is formed and drains into the internal iliac veins. The 
lubrication depends directly on the vessels, where an increased perfusion results in an 
increased passage of transudate through the vessel wall. The vessel function is controlled by 
the autonomic innervation [4].  
1.1.3 Innervation 
 
The innervation of the female genital tract is a delicate interplay between the autonomic 
nerves, both of sympathetic and parasympathetic origin, involving the pudendal nerve, the 
hypogastric plexus and the pelvic splanchnic nerve. The vaginal nerves are essentially 
derived from the uterovaginal plexus. The dorsal nerve of the clitoris is a branch from the 
pudendal nerve (S2-S4) and innervate the clitoris, labiae and the bottom third of the vaginal 
mucosa and the vulva. The hypogastric nerves innervate the upper 2/3 parts of the vaginal 
mucosa and control lubrication by regulating the blood flow. In men, who have undergone 
surgery for prostate and rectal cancer, the hypogastric nerve branches are uncovered at 
nerve-sparing surgery to maintain erectile function. Nerve-sparing surgery is not yet the 
standard in radical hysterectomy, but has started to be performed at some clinics [4]. Other 
effects of peripheral neuropathy may be changes in the pelvic floor muscles and neurogenic 
bladder disorder. Damage to the sacral nerves and their peripheral branches can also be 
associated with dyspareunia (pain during intercourse), or loss of sensation in the lower 
genital tract [5]. The sensory innervation of the upper part of the vagina is sparse compared 
to the lower part, which is abundantly supplied with free nerve endings [6].  
 
Several studies have evaluated the innervation of the vaginal wall by analyzing the staining 
of protein gene product 9.5 (PGP 9.5), a neural marker for peripheral nerves and ganglia 
[7]. In women with pelvic organ prolapse, a decreased number of subepithelial nerve fibers 
have been seen in the anterior wall [8], but there are conflicting results in studies evaluating 
the innervation in the posterior wall. Increased nerve fibers were seen in women with pelvic 
organ prolapse by using PGP 9.5 antibodies [9], but fewer nerve bundles when using 
antibodies to protein S100 [10]. 
1.1.4 Histology 
Histologically, the vaginal wall consists of four layers; the epithelium (against the lumen), the 
subepithelial layer or lamina propria (connective tissue), the smooth muscle layer and the 
adventitia [11]. The epithelium and the lamina propria are usually referred to as the mucosa 
(Figure 1). 
The epithelium is lined with a superficial non-keratinized, stratified, squamous epithelium, 
consisting of basal, parabasal, intermediate and superficial squamous cells. As the stratum 
corneum is missing also the top cells retain their cell nuclei. The epithelial thickness varies 
with the menstrual phase and age. After the proliferation phase the top layer of cells are 
removed during menstruation. During high estrogen levels in the follicular phase the 
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epithelial cells form glycogen, which gives the cells a characteristic pale appearance with 
rounded shapes, smaller nuclei and perinuclear clearing [12].  
 
 
 
Figure 1. An illustration of the vaginal wall, with the mucosa (the epithelium and lamina 
propria), the smooth muscle layer and the adventitia. Illustration by Bo Blomgren. 
 
Under the epithelium is the subepithelial layer, or the lamina propria, composed of a 
connective tissue layer with collagen and elastic fibers that are surrounded by an extracellular 
matrix (ECM). It is moderately cellular, with fibroblasts and smooth muscle cells and 
contains numerous capillaries and small lymph vessels. The basal membrane zone, between 
the epithelium and the underlying connective tissue, is formed with wrinkles. In healthy 
women before menopause numerous dermal papillae, consisting of connective tissue with 
capillaries, project into the epithelium supplying the epithelial cell layer. If the epithelium 
loses its dermal papillae, the epithelium will become thinner as necessary nutrients and 
oxygen supply no longer can reach the upper cell layers. The vaginal mucosa is one of few 
epithelia in the body, which are free of glands. The smooth muscle layer consists of an inner 
circular and an outer longitudinal layer. Finally, the adventitia surrounds the muscle layer, a 
loose connective tissue containing large venous plexus [11].  
1.1.4.1 Biochemical aspects of the vaginal connective tissue 
 
Elastin and collagen are the components that regulate the biomechanical properties of the 
vaginal wall. Elastin fibers provide elasticity and collagen fibers are very rigid. The ECM is 
constant remodeling, mediated by matrix metalloproteinases (MMPs), growth factors and 
signaling issued from the ECM itself [7]. Elastic fibers consists of an elastin core surrounded 
by proteins, such as fibulin-5, which promote elastogenesis and is crucial for the assembly of 
normal elastic fibers [13]. Fibulin-5 regulates the activity of the enzyme metalloproteinase 9 
(MMP9) [14].  
 
Collagen I, III and V are the main collagen subtypes in the vagina [15]. The collagen 
molecules, the tropocollagens, are made of three protein chains, coiled together to form a 
triple-helix [16]. Collagen I forms large and strong fibers, and collagen III and V form 
smaller fibers. The strength of the tissue depends on the proportion of each subtype and the 
cross-links that bind the tropocollagens together. 
 
  4 
1.2 CERVICAL CANCER 
1.2.1 Epidemiology 
 
Cervical cancer is globally the fourth most common cancer in women, after breast cancer, 
colorectal cancer and lung cancer. In some developing countries in Eastern and Middle 
Africa it remains the most common cancer. The latest statistics from 2012 showed 528,000 
new cases and 266,000 deaths from cervical cancer worldwide, accounting for 7.5 % of all 
female cancer deaths. Almost 9/10 (87 %) of cervical cancer deaths occur in less developed 
regions, where it accounts for around 12 % of all female cancers. High-risk areas include 
Eastern, Middle and South Africa and the Melanesia	  (Figure 2) [17].	  
 
 
 
 
Figure 2. Estimated cervical cancer incidence worldwide 2012 (GLOBOCAN 2012, 
www.globocan.iarc.fr).  
 
Gynecological cancer affects around 3,000 women per year in Sweden, of which cervical 
cancer represented 549 new cases in 2014 [18]. In Sweden the incidence of cervical cancer 
has decreased during the last 50 years, as a result of the organized screening program [19, 
20]. However, during the last years the incidence has slightly increased (Figure 3). 
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Figure 3. Cervical cancer incidence and mortality, Sweden 1952-2014 (NORDCAN 
database, www-dep.iarc.fr). 
 
Cervical cancer primarily affects young and middle-aged women; the average age is around 
50 years, about 30 % are under 40 years and 10 % are under 30 years. In Sweden, the 
mortality rate is low, especially in the younger women (Figure 4). 
 
 
Figure 4. Cervical cancer age-specific incidence and mortality, Sweden 2014 (NORDCAN 
database, www-dep.iarc.fr). 
1.2.2 Etiology and prevention 
 
Cervical cancer is a sexually transmitted disease caused by a persistent infection with high-
risk human papilloma virus (HPV) [21]. The oncogenic types 16 and 18 are the most 
common cancer-causing HPV types worldwide, found in about 70 % of all cases of 
invasive cervical cancer [22]. HPV infection is common in sexually active populations and 
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the majority of the HPV infections heal spontaneously within two years [23]. Only very 
few women develop a persistent HPV infection, implying the involvement of cofactors, 
which are still not fully known. Smoking is a known risk factor. Nicotine and other 
degradation products from smoking ends up in the mucus secreted by the glands of the 
cervix and accumulate on the epithelium [24]. Other known risk factors are multi-parity, 
concomitant genital infections, use of oral contraceptive and immunosuppression [25]. 
There is no proven hereditary form of cervical cancer, but as the immune system is 
involved genetic factors may play a role [26]. 
 In	  Sweden,	  the	  screening	  program	  with	  Papanicolaou	  (Pap)	  smear	  started	  in	  1966	  and	  since	  1977	  there	  is	  a	  functioning	  program	  in	  all	  county	  councils	  [27].	  The	  National	  Board	  of	  Health	  and	  Welfare	  (Socialstyrelsen)	  guidelines	  from	  2017	  form	  the	  basis	  for	  the	  screening	  program	  in	  terms	  of	  test	  method,	  age	  limits	  and	  intervals.	  The screening 
program, including HPV-testing, has shown a 60-70 % greater protection against invasive 
cervical cancer compared to cytology alone [28]. Women in Sweden are today offered 
liquid-based cytology between 23 and 64 years of age, and all women older than 30 years 
are tested for HPV. In 2015 the screening age was extended from 60 to 64 years of age. 
Testing is offered every third year for women between 23-49 years of age, and thereafter 
every seventh year [29]. For increasing participation in the cervical cancer screening, 
programs with a HPV self-test have been suggested for non-participants [30]. 
 
Organized Pap smear screening reduces the cervical cancer incidence [31] and HPV 
vaccination programs will hopefully further reduce the incidence in the future. The vaccines 
available today are all protecting for the two high-risk HPV types 16 and 18, showing 
protection against precancerous lesions [32]. A quadrivalent HPV vaccine also protects for 
HPV 6 and 11, which cause benign condyloma [33, 34]. A	  nine-­‐valent	  vaccine	  adds	  protection	  for	  HPV	  31,	  33,	  45,	  52	  and	  58.	  The	  first	  vaccination is recommended before 
the sexual debut. In Sweden, the HPV vaccine has been subsidized for 10-12 years old girls 
in the National Vaccine program since 2012. The vaccines are prophylactic and the 
introduction has not changed the recommendation in the organized screening programs 
[35].  
1.2.3 Clinical signs, diagnosis and staging 
 
Women with early-stage cervical cancer often show no clinical signs. When clinical 
symptoms are present, the most common are postcoital bleeding, irregular bleeding and 
vaginal discharge. The diagnosis is based on histology of biopsies. Staging of cervical 
cancer according to definition from International Federation of Gynecology and Obstetrics 
(FIGO) is based on clinical examination performed during anesthesia [36] (Table 1, Figure 
2). Lymph node status is not taken into account in this staging system. Since lymph node 
status is an important prognostic factor [37], it has recently been decided that the 
international recommendation will change to the use of the TNM (Tumour, Nodes, 
Metastasis) staging system in the future (Table 1).  
 
According to the Swedish national guidelines for the radiological basis for staging of 
cervical cancer, examination with magnetic resonance imaging (MRI) of the pelvis and 
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computed tomography (CT) of the thorax and abdomen are recommended, except for 
cervical cancer stage IA1. Additional positron emission tomography (PET) scan is 
recommended in women planned for primary definitive radiochemotherapy and in all cases 
of neuroendocrine histology [38]. 
1.2.4 Histology 
 
The squamous cell carcinoma is the most frequent histological type and accounts for       
80-90 % of the cases of cervical cancer, followed by adenocarcinoma (10-20 %) and 
adenosquamous carcinoma (3-5 %) [39]. In Western countries, the relative proportion of 
cervical adenocarcinoma has increased over the last 50 years [40, 41]. One possible 
explanation is that the screening methods are more effective detecting squamous cell cancer 
compared with adenocarcinoma [42]. Glassy cell carcinoma and neuroendocrine small cell 
carcinoma are more unusual subtypes, with poorer prognosis [43, 44]. 	  Table	  1.	  Stages	  of	  cervical	  cancer	  according	  to	  FIGO	  nomenclature	  [36]	  and	  the	  TNM	  staging	  system	  [45].	  
 *Regional	  lymph	  nodes	  include	  paracervical,	  parametrial,	  hypogastric	  (obturator),	  common,	  internal	  and	  external	  iliac,	  presacral	  and	  sacral.	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Figure 5. Staging of cervical cancer according to FIGO, stage IA1-IVB (from Quinn el al. 
[46]). 
1.2.5 Treatment 
 
The treatment of cervical cancer can include surgery, radiation and chemotherapy 
depending on the stage at diagnose. Microinvasive cervical cancer (FIGO stage IA1) is 
usually cured by simple hysterectomy or cone biopsy. In stage IA2 or IA1 with 
lymphovascular space involvement (LVSI) radical hysterectomy or trachelectomy, with 
additional pelvic lymph node dissection is recommended [38, 47, 48]. Surgery and 
radiotherapy are reported to be equally effective in cervical cancer stage IB1 and IIA1 [49]. 
Primary radical surgery with radical hysterectomy and pelvic lymph node dissection is 
usually the choice of treatment due to the risk of side effects by radiotherapy. Primary 
surgery is not recommended in patients with preoperatively diagnosed large tumors (more 
than 4 cm) or lymph node metastasis, since treatment including radical hysterectomy and 
radiotherapy have shown to give more side effects, compared to treatment with surgery or 
radiotherapy alone [50, 51]. In patients with unfavorable prognostic factors after surgery, 
such as lymph node metastasis and positive resection margins, adjuvant chemoradiation has 
shown to increase the progression-free survival at 4 years from 63 to 80 % and overall 
survival from 71 to 81 % compared with radiotherapy alone [52]. 
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Previously, preoperative intracavitary brachytherapy (BT) was often used at Karolinska 
University Hospital for early stage of cervical cancer (at that time stage IB-IIA). The 
treatment included two intracavitary radiotherapy applications with a three-week interval, 
followed by surgery [53]. Currently, standard treatment for locally advanced cervical 
cancer (FIGO stage IB2, IIA2-IVA) includes external beam radiotherapy and intracavitary 
radiotherapy combined with weekly intravenous cisplatinum [54]. In stage IB2, IIA2 and 
IIB the risk for lymph node metastasis are reported to be between 19 to 44 % [55, 56], 
resulting in the recommendation of primary definitive radiochemotherapy. 
1.2.5.1 Surgery 
 
Standard radical surgery for cervical cancer stage IA2, IB1 and IIA1 includes radical 
hysterectomy with complete resection of the parametria and the paracervical tissue, pelvic 
lymphadenectomy and resection of the proximal portion of the vagina [57]. For early stages 
(IA2, IB1) radical trachelectomy and pelvic lymphadenectomy can be an alternative 
treatment for preserving fertility. For safety this option requires tumor size less than 2 cm 
and no high-risk tumor histology [58]. 
 
Primary radical surgery can be performed by laparotomy or robot-assisted laparoscopic 
surgery. Studies on robot-assisted laparoscopic surgery indicate less per-operative bleeding 
and shorter hospital stay with fewer complications compared to open surgery [59-62]. Still, 
today laparotomy is considered the gold standard surgical management, due to the lack of 
randomized clinical trials [63, 64]. Ovarian preservation is recommended in premenopausal 
women, except in cases of larger adenocarcinoma (more than 2 cm) [65]. 
 
Nerve-sparing surgical techniques have shown to improve	  postoperative	  quality	  of	  life,	  with	  less	  impaired	  bladder	  function	  [66]	  and	  less	  impaired	  sexual	  function	  [67].	  
1.2.5.2 Radiotherapy 
 
Definitive radiochemotherapy for cervical cancer including external beam radiotherapy 
(EBRT), intracavitary radiotherapy (brachytherapy) and concomitant weekly cisplatin is 
standard treatment for cervical cancer stage IB2, IIA2-IVA [54]. EBRT over a pelvic field 
includes the internal and external iliac nodes, the lower common iliac nodes up to the level 
of the space between the lumbar vertebrae L4 and L5. The treatment is usually delivered 
with a daily fraction of 1.8-2.0 Gy to a total dose of 45-50 Gy. 
 
Brachytherapy is of great importance for the success of the cervical cancer treatment [68, 
69]. Until the last decade, the intracavitary BT dose was prescribed to the “Point A”, 
located 2 cm proximal from the mucous membrane of the lateral fornix and 2 cm lateral of 
the central axis of the uterus, introduced by the Manchester system [70]. Today, MRI-based 
3D treatment planning of the BT is recommended, according to European recommendations 
[71-74] and American guidelines [75-78]. In MRI-based image guided adaptive 
brachytherapy (IGABT), with repeated volumetric imaging, the treatment planning adapts 
to the reduced tumor volume over time. Studies have shown both reduced normal tissue 
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toxicity and better local tumor control [79, 80]. Treatment combining the intracavitary BT 
with interstitial BT, in which needles are inserted to the tumor has shown both superior 
target coverage and organ sparing, compared to intracavitary BT alone [81]. BT can be 
delivered by different dose rates. High dose rate (HDR) treatment is the most frequently 
used worldwide. In Sweden, today, HDR or pulsed dose rate (PDR) are the used 
techniques. PDR delivers the HDR in a number of fractions during a longer period of time, 
which radiobiologically resembles LDR (low dose rate).  
 
A total radiation dose to the high-risk clinical target volume (HR-CTV) of D90% > 85 Gy, 
converted to biologically equivalent dose in 2 Gy fractions (EQD2), is considered necessary 
for local tumor control [82, 83]. A more recent retrospective study has shown that D90% ≥ 
87 Gy to the HR-CTV reduced the risk for local recurrence from 20 % to 4 % [84]. Modern 
radiotherapy modality like intensity modulated radiation therapy (IMRT), gives a more 
individually optimized treatment [85].  
 
Concomitant chemotherapy during the radiotherapy, with weekly cisplatin, is given to 
enhance the radiosensitivity in the tumor cells [86]. It is today a standard treatment based 
on meta-analysis showing a 6 % improvement in the 5-year survival rate, compared to 
radiotherapy alone [87].  
 
Adjuvant radiochemotherapy after radical surgery is indicated in cases of unfavorable 
prognostic factors, such as lymph node metastasis, positive surgical margins, tumor growth 
in parametria, tumor size more than 4 cm, LVSI, growth in the outer 1/3 of the stroma or 
small cell neuroendocrine histology [38, 88, 89]. Standard treatment is EBRT to a pelvic 
field with a minimum dosage of 45 Gy, and five courses of concomitant weekly cisplatin. 
In cases of large tumor size and/or close surgical margins, vaginal boost given to the upper 
1/3 part of the vagina, should be considered [38]. 
1.2.6 Survival and prognostic factors 
 
The prognosis of patients with cervical cancer is related to tumor stage. In the FIGO 26th 
annual report including data from 37 countries, with 11,775 women treated 1999-2000, the 
stage was the most important prognostic factor [46]. Women diagnosed in stage IA1 had a 
5-year survival of 98 % compared to 9 % for women in stage IVB. Other important 
prognostic factors are lymph node status and tumor size [46].  
 
In Sweden the overall 5-year survival rate for cervical cancer is 73 % reported in 2014 [18]. 
A majority of patients diagnosed with cervical cancer are young or middle-aged women 
with a long life expectancy and will live many years with the chronic side effects of the 
treatment.  
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1.3 SEX STEROID HORMONES IN WOMEN 
 
Estrogen, progesterone and androgen, the sex steroid hormones, are mainly synthesized in 
the gonads and the adrenal cortex. The system of female hormone production consists of 
different levels, the hypothalamus, the central regulator, through the hypothalamic-
pituitary-ovarian and the hypothalamic-pituitary-adrenal axes. From the anterior pituitary 
gland follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are released after 
stimulation by gonadotropin releasing hormone (GnRH) from the hypothalamus. The 
ovarian hormones estrogen and progesterone are secreted in response to FSH and LH [90]. 
 
The main site of estrogen synthesis differs between pre- and postmenopausal women. In 
premenopausal women, estrogens are mainly produced in the granulosa cells of the ovary 
during the menstrual cycle, while lower levels of estrogen are also produced in the bone, 
muscle, fat and vascular tissue and the brain [91]. In the follicular phase the secretion of 
FSH rises whereas LH remains low. FSH stimulates the growth of follicles in the ovaries 
leading to increased estradiol production. Via a feedback loop a high level of LH is 
established, which induces ovulation. After ovulation estradiol levels fall and the corpus 
luteum is formed. In the luteal phase, the corpus luteum produces estradiol and 
progesterone, which have an inhibitory effect on the secretion of FSH and LH. If 
fertilization does not occur, the corpus luteum degenerate and the secretion of sex steroid 
hormones drop, which initiates the menstrual bleeding. 
 
Menopause is defined as the time when there has been no menstrual period for one year, 
with no other identified biological or psychological cause. Natural menopause is the 
physiological transition when the ovulations stop, the cyclic ovarian secretions of female 
sex steroid hormones disappear and the menstrual periods finally end. Consequently, the 
level of FSH will increase. The mean age of menopause in Sweden is 51 years [92]. 
Iatrogenic early menopause can be caused by cancer treatment, with radiotherapy, 
chemotherapy or by surgery [93]. In postmenopausal women the main sites of estrogen 
synthesis are the adipose tissue, bone, liver and brain [94]. Estrogen synthesized in the extra 
gonadal sites acts mostly locally, in contrast to ovarian-synthesized estrogen produced in 
premenopausal women, which is mainly released into the circulation [95].  
1.3.1 Estrogens 
 
Estrogens are C18 steroids derived from cholesterol. The primary source of estradiol in 
woman is the granulosa cells of the ovaries. Estrogens are synthesized from androgens by 
the enzyme aromatase. The estrogen with most estrogenic activity is estradiol (E2, or 17β-
estradiol); whereas estrone (E1) and estriol (E3) have much weaker activity. E2 is the most 
potent estrogen in premenopausal women, while E1 is more important in postmenopausal 
period. E1 is then synthesized from adrenal androstenedione in fat tissue. E3, the least 
potent estrogen, is formed from E1 in large amount during pregnancy by the placenta. For 
transportation in the blood, 69 % E2 is reversibly bound to sex-hormone-binding globulin 
(SHBG), 30 % bound to albumin and only 1 % is freely circulating [90]. SHBG binds with 
lesser affinity to estradiol, compared to its high affinity binding to testosterone [96]. SHBG 
is synthesized in the liver cells and both the natural estradiol and the synthetic ethinyl 
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estradiol increase the production [97]. In use of oral contraceptives with ethinyl estradiol, 
the plasma levels of SHBG rise by at least 5-fold [98], further decreasing the levels of the 
free testosterone [99]. In postmenopausal women using hormone replacement therapy 
(HRT), plasma levels of SHBG has been reported to increase following oral HRT, but were 
not affected by transdermal HRT [100]. If this finding has any clinical implication in HRT 
users is not known. 
1.3.2 Steroid hormone receptors  
 
The steroid hormone receptors are a subset of proteins within the nuclear receptor family 
that initiate signal transduction for steroid hormones, which lead to changes in gene 
expression in the target tissue [90]. Nuclear receptors are ligand-activated transcription 
factors that control the rate of transcription of genetic information from DNA to messenger 
ribonucleic acid (mRNA). These receptor protein chains are folded into domains with 
specific functions [101].  
 
The genomic pathway mediates the transcription of gene segments to mRNA in the nucleus 
and the subsequent translation to specific proteins in the target tissues, within hours. The 
non-genomic pathway, with rapid effects (within seconds) involves the interaction with 
membrane recognition site of the steroid hormone [102]. 
 
The estrogen receptor (ER) has two subtypes, ERα and ERβ. The presence of ERα was 
discovered in 1958 [103] and in the 1990s the ERβ was identified [104]. The two isoforms 
may explain some of the different estrogen responses in different tissues. They have 
similarity in ligand binding affinity, but appear to activate transcription differently [105]. 
The ERs have the highest affinity to estradiol, less to estrone and ever weaker to estriol. 
ERα and ERβ share many functional characteristics, but the regulation of transcription 
activity and the tissue locations are different. The roles of these receptors have been 
clarified in female reproduction by studying knockout mice [106]. ERα is suggested to have 
proliferative effects in most tissues, whereas ERβ has an anti-proliferative and pro-
differentiative effect [107]. The tissue distribution of the ERs is overlapping. ERα is present 
in the urogenital tract, breast, brain, cardiovascular system, liver and in bone. The ERβ 
subtype has been identified in the urogenital tract, kidney, brain, bone, heart, lungs, 
gastrointestinal tract and endothelial cells [107].  
 
The progesterone receptor (PR) exists in two isoforms, A and B that originate from the 
same gene. PRA and PRB are almost identical, but PRA is shorter, lacking 164 amino 
acids, compared to PRB. The PR and ER expression in the human endometrium increases 
during the follicular phase and decreases during the luteal phase of the menstrual cycle 
[108, 109], but in the outer portion of the uterine wall a cyclic pattern of ER and PR 
expression is not found [110].	  In	  postmenopausal	  women	  without	  HRT,	  high	  stabile	  expression	  of	  both	  ER	  and	  PR	  were	  found	  in	  all	  the	  uterine	  layers,	  suggesting	  that	  the	  expression	  of	  ER	  and	  PR	  is	  essential	  for	  the	  uterine	  tissue	  [110].	  In	  the	  luteal	  phase,	  when	  the	  progesterone	  level	  is	  high,	  ER	  expression	  in	  the	  human	  breast	  tissue	  is	  down	  regulated,	  while	  PR	  expression	  in	  the	  breast	  remain	  high	  throughout	  the	  normal	  menstrual	  cycle.	  However,	  under	  influence	  of	  exogenous	  gestagens	  both	  ERs	  and	  PRs	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are	  down	  regulated	  [111],	  indicating	  the	  complexity	  of	  the	  steroid	  receptor	  expression	  being	  affected	  of	  both	  the	  hormonal	  status	  and	  the	  target	  tissue.	  	  
The androgen receptor (AR) exists in a long A-form and a shorter B-form. The AR 
expression has been documented in numerous tissues, including the central nervous system, 
urogenital tract, breast, bone, muscle and cardiovascular system. The AR is most closely 
related to the PR and progestin (synthetic progesterone) in high dosage can block the AR 
[112]. Consequently, progestin may act as an antiandrogen as well as an antiestrogen.  
 
In female genitals the expression of ERα and PR gradually decrease from the vagina to the 
vulva, whereas the highest concentration of AR is found in the vulva [113]. ERα and ERβ 
mRNAs have been demonstrated in extracts from vaginal tissue, with the highest level of 
expression in premenopausal women. Postmenopausal women receiving HRT showed the 
lowest mRNA ERα expression. No differences were seen in ERβ expression between 
postmenopausal women with or without HRT [114]. 
 
In pre- and postmenopausal women with prolapse, IHC showed higher expression of ERα 
in the premenopausal group both in the anterior and the posterior walls, with a positive 
correlation to the concentration of blood vessels [115]. In one study, treatment with local 
estrogen therapy was leading to increased ERα and PR expression in the posterior wall in 
postmenopausal women with prolapse, while ERβ expression was almost unchanged [116].  
Table 2 presents previous studies on sex steroid hormone receptor expression in the vaginal 
wall. There are no studies on the steroid receptor expression in the vaginal wall after 
treatment of cervical cancer with radiotherapy.  
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Table 2. Studies on sex steroid hormone receptor expression in the vaginal wall. 
 
 
Study objects Study design Results 
Van Haaften, 
1997 [117] 
Women 
(n=29) 
ERc, PRc and ERn in the 
endometrium, myometrium and 
vagina in postmenopausal 
women treated with vaginal 
estriol (0.5 mg daily) compared 
to 17β-estradiol (0.05 mg daily) 
therapy. 
No differences between vaginal 
estradiol and estriol medication with 
regard to the effects on receptor levels 
in vaginal and uterine tissues. 
Chen, 1999 
 [118] 
Women 
planned for 
hysterectomy 
ERα, ERβ mRNA expression in 
premenopausal (n=12) and 
postmenopausal women (n=4) 
ERβ	  was	  absent	  in	  the	  vaginal	  walls	  of	  postmenopausal	  women.	  ERα	  were	  found	  in	  both	  groups.	  
Gebhart, 2001  
[114] 
Women 
(n=75) 
ERα, ERβ mRNA expression in 
premenopausal (n=25), 
postmenopausal with estrogen 
replacement therapy (ERT) 
(n=25) and postmenopausal 
without ERT. 
Postmenopausal lower ERα expression 
compared with premenopausal, but no 
difference between postmenopausal 
with ERT compared to premenopausal. 
Postmenopausal lower ERβ expression 
than premenopausal regardless of ERT.  
Pessina, 2006  
[119] 
 Rats IHC ERα, PR, AR in the vaginal 
wall was analyzed after 
oophorectomy, and treatment 
with estradiol, testosterone and 
progesterone. 
Oophorectomy resulted in an increase 
in ERα and a decrease in PR. Estradiol 
down-regulated ERα and up-regulated 
PR expression. AR unaffected.  
Söderberg, 2007  
[120] 
Women with 
stress urinary 
incontinence 
(SUI)/controls 
ERα, ERβ, PR, AR mRNA 
expression in women with SUI, 
premenopausal (n=4), 
postmenopausal (n=8). Controls 
premenopausal (n=6), 
postmenopausal (n=5) 
Higher ERβ in the premenopausal 
women with SUI, compared to controls. 
Lower PR scores in the postmenopausal 
groups. 
Baldassarre, 2013 
[121] 
Women with 
prolapse and 
women with 
testosterone 
treatment  
AR mRNA expression and IHC 
AR in mucosa and stroma in 
premenopausal (n=16), 
postmenopausal (n=16) and T-
treated women (n=16). 
Higher AR protein and mRNA 
expression in premenopausal compared 
to postmenopausal. Higher AR protein 
and mRNA expression after 
testosterone (T) administration. 
Lara, 2014  
[115] 
Women with 
prolapse 
IHC ERα and endothelial cell 
marker CD3 to label vessels in 
premenopausal (n=6) and 
postmenopausal women (n=6). 
Postmenopausal lower ERα expression, 
compared with premenopausal. A 
positive correlation between ERα and 
the vessel concentration. 
Fuermetz, 2015  
[116] 
Women 
corpses and 
biopsies  
IHC ERα, ERβ, PR in 
premenopausal corpses (n=60), 
postmenopausal corpses (n=43) 
and postmenopausal women 
treated with local estrogen 
therapy (n=80) 
ERα expression was higher in the 
epithelium and stroma in the 
postmenopausal women with local 
estrogen therapy. PR expression was 
increased in the group with local 
estrogen therapy. ERβ expression was 
unchanged. 
Sawczuk, 2017  
[122] 
Women 
(n=60),  
mean age in 
the three 
groups 53-60 
years 
IHC ERα, ERβ in smears of 
vaginal mucosa after using po 
estradiol (1 mg) therapy (n=20), 
transdermal estradiol (0.5mg 
+NETA) therapy (n=20) and 
vaginal estradiol 0.5 mg (n=20) 
in 3 months. 
Highest increase in intensity of ERα 
after topical therapy, lowest after oral 
therapy.  
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1.4 LATE SIDE EFFECTS IN CERVICAL CANCER TREATMENT 
 
Chronic side effects can either develop directly after acute toxicity or years after completed 
cancer treatment. Radiotherapy-induced acute radiation damage starts after exposure and 
symptoms develops gradually during the treatment course.  Reactions with symptoms 
presented more than three months after completed radiotherapy are considered to be late 
side effects [123, 124]. The degree of the radiation related toxicity depends on treatment 
factors such as total dose, dose per fraction, total treatment time, irradiated volume and type 
of radiation. Patient-related factors as comorbidity, smoking, age and additional treatments 
as surgery and chemotherapy may worsen the late side effects [125-127]. Vascular damage, 
fibrosis and neural damage are tissue response in the complex radiation injury [128, 129]. 
Acute vascular changes result in cellular damages, increased permeability and 
inflammation, which leads to vascular injury and hypoxia, causing chronic tissue damage 
[130]. This cascade of cytokine activation and further oxidative stress creates a dynamic 
process promoting collagen formation [131]. Better knowledge in these mechanisms 
hopefully could lead to new approaches towards prevention of side effects [132]. 
 
Radical hysterectomy with pelvic lymph node dissection for early cervical cancer can be 
associated with long-term morbidity with sexual, bladder and bowel dysfunction [133]. 
Hopefully, new surgical nerve-sparing techniques will reduce the postoperative side effects, 
but is not yet the standard in all centers [4]. 
 
The late side effects of radiotherapy on the surrounding pelvic structure, with 
morphological changes and symptoms on bladder and intestine, are well documented [134, 
135]. The cancer survivors report gastrointestinal symptoms of diarrhea, defecation 
urgency, fecal incontinence and abdominal pain after pelvic radiation [136-138], symptoms 
associated with distress [139]. Bleeding from the bowel, fistulas between vagina and 
bladder or rectum are examples of severe late side effect after radiotherapy for cervical 
cancer [140]. Urinary symptoms with voiding difficulties and urinary incontinence can 
occur postoperatively after radical hysterectomy or after combination treatment with 
surgery and adjuvant radiotherapy [141]. Urological late side effects after radiotherapy are 
hematuria, dysuria, shrunken fibrotic bladder, ureteral stenosis and fistulae [142]. 
1.4.1 Sexual dysfunction after cervical cancer treatment 
 
Women who have been treated for cervical cancer often report persistent changes in their 
sexual function, which results in considerable distress and decreased quality of life [143]. 
The World Health Organization define sexual health as a state of physical, emotional, 
mental and social well-being in relation to sexuality [144]. Female sexual dysfunction 
refers to persistent problems with the sexual response cycle; desire, arousal and orgasmic 
phase or sexual pain, that results in personal distress [145]. Epidemiological studies of the 
general population in the United States have shown prevalence of sexual dysfunction in 
women to approximately 40 % [146, 147]. The prevalence among gynecological cancer 
survivors differs in previous reports from 48 % up to 90 % [148-150]. The difference can 
be due to methodological variations, heterogeneity regarding patients’ groups and/or the 
use of various questionnaires.  
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Cervical cancer is often diagnosed in young or middle-aged women, who are usually 
sexually active [151]. The gynecological tumor and the treatment with surgery, radiation 
and/or chemotherapy directly affect the reproductive and sexual organs. The sexual 
dysfunction in cervical cancer survivorship could start directly after treatment [152] and 
persist in long-term survivors [153, 154]. Women treated with radiotherapy have shown 
worse sexual functioning compared to survivors treated with surgery alone [155, 156]. 
There are reports on sexual function after radical hysterectomy alone showing no adverse 
impact [155]. However, other studies have shown negative effects, such as insufficient 
lubrication, reduction in vaginal length and elasticity [143]. In a large longitudinal study, 
persistent negative impact on sexual interest and vaginal lubrication was found, but the 
other sexual problems, such as orgasmic difficulties, reduced vaginal size and dyspareunia 
ended over time [157].  
 
Cervical cancer and its treatment can affect the different stages in the sexual response cycle 
[158]. Desire has been reported to be decreased after different treatment modalities, such as 
radical hysterectomy [157] and treatments including radiotherapy [159, 160]. The 
prevalence of decreased lubrication when sexually aroused have been reported after surgery 
alone [161], after combined treatment with surgery and radiotherapy and after primary 
radiotherapy [143, 162, 163]. Vaginal dryness of various degrees has been reported after all 
treatment modalities [161, 164-166]. Reduced frequency of orgasm is reported after 
treatments with surgery and radiotherapy [155, 157] and after primary radiotherapy [162], 
but there are also reports where no differences were found between cancer survivors and 
controls in this aspect [143, 165, 167]. A higher prevalence of dyspareunia has been 
reported in several studies comparing cervical cancer survivors versus healthy control 
women [143, 157, 162, 165, 167]. Significantly more dyspareunia in cervical cancer 
survivors treated with surgery and radiotherapy, compared to survivors treated with surgery 
or radiotherapy alone, where found by Park et al. [167]. In contrast, Pieterse et al., found no 
increased risk of dyspareunia of adjuvant radiotherapy following surgery [165].  
 
The pathophysiology of the genital symptoms and sexual dysfunction in cervical cancer 
survivors can be explained by multiple factors. Radical hysterectomy can cause pelvic 
autonomic nerve damage [168, 169], which may affect the neural vascular control with 
genital swelling and lubrication response during sexual arousal [170]. Surgery also causes a 
direct shortening of the vagina and risk of postoperative fibrosis in the proximal part. 
Fibrosis and vascular changes can also be caused by radiotherapy [171]. Collagen 
deposition is described as a part in the defect tissue healing in other irradiated tissues [128, 
172]. The hormonal changes with reduction in estrogen as a consequence to oophorectomy 
or radiotherapy can lead to thinning of the vaginal wall and attenuated genital blood flow 
[173]. Psychological factors can affect sexuality in cancer survivors by stress, anxiety, 
depression and negative sexual body image [174, 175]. 
1.4.2 Vaginal changes after radiotherapy in cervical cancer survivors 
 
Vaginal stenosis after radiotherapy, defined as an abnormal vaginal tightening and 
shortening due to the formation of fibrosis, is a common late side effect in cervical cancer 
  17 
survivors [176]. In the literature, there is a variation in prevalence from 38 % to 88 % [177-
180]. The variation can be due to tumor-, treatment- and patient-related factors.  
The interpretation of previous studies is further complicated by the use of different grading 
systems. In the National Cancer Institute Common Terminology Criteria for Adverse 
Events (CTCAE) v.3.0, vaginal stenosis was defined as vaginal narrowing and/or 
shortening; not interfering with function (grade 1), interfering with function (grade 2) and 
as complete obliterated (grade 3). In the new version CTCAE v4.0, vaginal stenosis is 
replaced with vaginal stricture (characterized by narrowing of the vaginal canal); 
asymptomatic, mild (grade 1), narrowing and/or shortening not interfering with 
examination (grade 2), narrowing and/or shortening interfering with sexual activity or 
examination (grade 3). Other grading systems for morbidity after radiotherapy are the 
Franco-Italian Glossary [181] and the Late Effects in Normal Tissues-Subjective, 
Objective, Management and Analytic Score (LENT-SOMA) [182]. Kirchheiner et al. have 
described different degrees of vaginal changes based on vaginoscopy images [183].  
 
Radiation induced injuries in capillaries with dilatation can manifest as telangiectasia, 
abnormal superficial vessels in the mucosa, which can bleed during sexual intercourse and 
at gynecological examination. Telangiectasias, as well as the signs of atrophy, are typical 
findings at gynecological follow-ups [183]. However, these findings are rarely graded in 
the clinical situation. Heavy smoking (>10 cigarettes per day) during radiochemotherapy is 
associated with severe late side effects, with a 3 % prevalence of total vaginal necrosis 
[184]. 
 
There are only a few previous studies analyzing vaginal biopsies after radiotherapy in 
cervical cancer survivors. Pitkin and Bradbury analyzed in 1965 punch biopsies from the 
vaginal fornix in women after radiotherapy, finding that thickness and maturation of the 
epithelium increased over time, reaching a maximum after two years. They also reported 
signs of epithelial regeneration in women treated with estrogen cream [185]. In contrast, 
Abitbol el al found no changes in vaginal cytology after women had been treated with 
systemic estrogen therapy [186]. In vaginal biopsies after radiotherapy, atrophic mucosa as 
well as hyalinization and collagenization of the connective tissue, was shown [186]. In 
1995 Shield showed similar findings in vaginal biopsies after radiotherapy with atrophy and 
stromal changes with fibrosis, vessel changes and atypical fibroblasts [187].  
 
In a placebo-controlled trail by Pitkin et al., women reported less vaginal bleeding and 
dyspareunia when treated with estrogen cream (0.01 % dienestrol) for 3 months, compared 
to women with placebo cream [188]. Table 3 presents previous studies on changes in the 
vaginal wall after radiotherapy in cervical cancer survivors, including studies on 
intervention with estrogen therapy and vaginal dilation. 
 
There is limited data on the irradiation tolerance dose of the vagina [189, 190]. A proposal 
to report dose-effect relationship between the radiation dose to the recto-vaginal reference 
point and the vaginal morbidity has been made in the EMBRACE study [191]. A dose ≤ 65 
Gy EQD2 to the recto-vaginal reference point was proposed for reducing the risk of vaginal 
stenosis ≥ grade 2 [191]. Further studies by Westerveld et al. have presented a method for 
reporting vaginal dose contributed of EBRT and BT along the vaginal axis [192]. They  
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further concluded that the dose at the mid vagina was reflecting the dose from BT, while 
the dose contributed to lower vaginal point was dependent of the EBRT field border 
location [193]. 
 
Table 3. Studies on changes in the vaginal wall after radiotherapy for cervical cancer; 
intervention with estrogen treatment and vaginal dilation. 
 Study objects Study design Results 
Vasicka, 1958  
[180] 
 
 
Women treated with 
RT (n=16), stage I-II, 
age <50 yrs 
Pelvic examination Vaginal stenosis 81 % 
Pitkin, 1965  
[185] 
Women treated with 
RT (n=49), age <50 
yrs, stage not stated, 
sexual intercourse > 
1/month, 1d-3yrs 
after RT. 
Cytological (vaginal smear) 
and histologic study (punch 
biopsies from the fornix). 
Treatment with estrogen 
cream (0.01 % dienestrol) 
for 3 months (n=31) vs. 
treatment with cream 
without estrogen (n=7). 
The thickness and maturation of 
the epithelium increased over 
time after end of RT, with a 
maximum after 2 yrs.  
Treatment of estrogen cream had 
a significant effect on epithelial 
regeneration, especially in 
patients post-RT >3 months.  
Griffin, 1968  
[194] 
Women treated with 
RT (n not stated) 
Clinical examination Fibrous connective tissue, 
telangiectasia, vaginal 
shortening, loss of functional 
vagina 
Pitkin, 1971  
[188] 
Women treated with 
RT (n=93), stage I-IV 
Double-blind, placebo-
controlled, topical estrogen 
therapy (0.01 % dienestrol 
cream, 3 times/w, 5-8 
months) (n=44) vs placebo 
(n=49), clinical 
examination 
The estrogen-treated group had 
less vaginal bleeding and the 
vaginal epithelium was 
considered normal in appearance 
in 43 % vs 10 % in controls. 
Frequency of intercourse was 
equal, but the estrogen-treated 
group reported less dyspareunia. 
Hartman, 1972 
[179] 
 
Women treated for 
cervical cancer 
(n=221), stage I-IV 
Retrospective study, 
medical records 
Vaginal stenosis 88 % 
Abitbol, 1974  
[186] 
 
Women, at least 1 
year after end of 
treatment for cervical 
cancer st I-II (n=97), 
23-68 yrs 
Surgery alone (n=41) 
Primary RT (n=37) 
Comb (n=19) 
Pelvic examination 
Gross appearance and 
vaginal cytology after RT 
(n=17) and after surgery 
alone (n=13). Vaginal 
biopsies after surgery 
(n=7). Vaginal cytology 
before and after systemic 
estrogen therapy (2.5 mg 
conjugated estrogen, 
Premarina®, daily for 1 
week) in the group that had 
received RT (n=17). 
After radiation narrowing or 
vaginal obliteration (81 %), 
pelvic fibrosis, telangiectasia. 
Atrophic mucosa, hyalinization 
and collagenization of the 
connective tissue, the muscular 
coat of vessels was thickened 
with fibrotic tissue, which 
replaced the muscular fibers.  
No change in vaginal cytology 
after estrogen therapy. 
Pitkin, 1975  
[195] 
 Letter to the Editor, 
discussing the study above 
by Abitbol. 
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Poma, 1980  
[196] 
Women treated with 
RT with complete 
vaginal occlusion 
(n=5), stage II 
Case report. Measuring the 
vagina, after digital 
pressure and topical 
estrogen therapy twice a 
day for 6-8 weeks. 
The five women received a 
functional vagina, length 10 cm, 
at end of treatment. 
Bruner, 1993  
[178] 
Women treated with 
RT for cervical 
cancer (n=42), and 
endometrial cancer 
(n=48), age 30-83 yrs 
Vaginal length was 
measured, before treatment, 
6-12 month, 1-2 years and 
>2 years after treatment 
Vaginal stenosis 72 %. Vaginal 
length decreased over time, 
greater in patients treated for 
cervical cancer, and greater in 
patients with more advanced 
stage.  
Shield, 1995  
[187] 
Women treated with 
RT (n=24) (9 were 
also treated with 
surgery). Age not 
reported. 
Cervicovaginal smear  
Vaginal biopsies (n=11), 
collected 6 weeks to 4.5 
years after RT. 
 
Fibrosis, hyalinization, bizarre 
fibroblast in the stroma. Atrophy 
in 76 % of the biopsies. Smears 
showed atrophic pattern in 88 %, 
and large amount of “atypic 
cells”. 
Grigsby, 1995  
[171] 
Review Review of late effects of 
cancer treatment of the 
female reproductive tract. 
Grading system, tolerance doses, 
management strategies. 
Decruze, 1999 
[197] 
Women treated with 
RT for cervical 
cancer (n=29), and 
endometrial cancer 
(n=41), age 35-87 yrs 
Retrospective study 
evaluating use of vaginal 
dilator (n=35), with a 
historical control group not 
using dilator (n=35). 
Vaginal exam, 3-12 months 
after end of treatment. 
Vaginal stenosis in 11 % of 
women in the group using a 
dilator, compared to 54 % in the 
controls. 
Brand, 2006  
[177] 
Women treated with 
RT (n=188), stage I-
IV, age 26-85 yrs 
Retrospective study, 
medical records, follow-up 
2.4-129 months. 
Vaginal stenosis grade 1-2 in 38 
% of the patients. Risk factor, 
age over 50 yrs. 
Guth, 2010  
[184] 
Women treated with 
RCT (n=98), stage I-
IV, age 26-84 yrs 
Retrospective study, 
medical records, focus on 
severe late toxic reactions, 
total vaginal necrosis. 
8.2 % severe late toxic reaction 
3.1 % total vaginal necrosis, risk 
factor smoking (>10/d). 
Kirchheiner, 
2012 [183] 
Women treated with 
primary RT +/- 
chemo (n=22), stage 
I-IV, age 35-76 yrs 
Vaginoscopy with photo 
documentation 3-24 months 
after end of treatment. 
Mucosal pallor, telangiectasia, 
fragility of the vaginal wall, 
ulceration, and 
adhesions/occlusion. 
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2 AIMS OF THE THESIS 
 
The overall aim was to improve our knowledge of the chronic side effects in cervical cancer 
survivors treated with radiotherapy, with particular focus on vaginal morphological changes 
and sexual dysfunction. 
 
The specific aims of the thesis: 
• To investigate the morphology of the connective tissue of the vaginal wall in cervical 
cancer survivors treated with radiotherapy, with focus on the amount and structure of 
elastin and collagen fibers. 
 
• To analyze the morphological changes in the vaginal epithelium in cervical cancer 
survivors treated with radiotherapy and its correlation to serum levels of sex steroid 
hormones and sexual function. 
 
• To study the amount and distribution of sex steroid hormone receptor expression 
(both on mRNA and protein levels) in the vaginal wall (epithelium and stroma) in 
cervical cancer survivors treated with radiotherapy.  
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3 PARTICIPANTS AND METHODS 
3.1 PARTICIPANTS (PAPERS I-III) 
 
All studies were conducted at Radiumhemmet, Karolinska University Hospital and at the 
Department of Clinical Sciences at Danderyd Hospital, Stockholm. The studies were 
approved by the Regional Research Ethics Committee in Stockholm (Dnr 2003-753) and all 
the participants signed a written informed consent. 
3.1.1 Cervical cancer survivors 
 
Cervical cancer survivors treated with radiotherapy, between January 1, 2004, and 
December 31, 2007, were identified from the medical records at Radiumhemmet, 
Karolinska University Hospital. Inclusion criteria were diagnosis of cervical cancer treated 
with radiotherapy and age ≤51 years (the mean age for menopause for Swedish women). 
The time from the end of treatment to participation in the study was from two to five years. 
Exclusion criteria were recurrence of cervical cancer and significant comorbidity. In 2009 
and 2010 letters explaining the objectives of the study were sent to the identified cervical 
cancer survivors inviting them to participate in the study (n=66). After one week, a research 
nurse telephoned the women. Of the total 66 cervical cancer survivors identified in the 
medical records, 34 women agreed to participate and were scheduled for a research visit 
(Figure 6).  
3.1.2 Control women 
 
As controls, 37 premenopausal women, aged ≤51 years undergoing benign gynecological 
surgery were recruited at Danderyd Hospital. Exclusion criteria for the controls were a 
history of cancer, current pregnancy, systemic disease, and vulvovaginal infections and/or 
inflammation. The most common reason for surgery among the control women was 
myoma. Conizations of the cervix uteri due to cervical dysplasia, laparoscopic surgery for 
sterilization, benign ovarian cysts or endometriosis were other causes for surgery. 
 
Characteristics of cervical cancer survivors and control women are summarized in Table 4 
and 5.  
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Figure 6. Flow-chart of the cervical cancer survivors in study I-III   
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Table 4. Cervical cancer survivor staging, histology and treatment. 
FIGO	  stage	  –	  no.	  (%)	   	  	  	  	  	  	  IB1	   16	  (47)	  	  	  	  	  	  IB2	   4	  (12)	  	  	  	  	  	  IIA	   6	  (17)	  	  	  	  	  	  IIB	   5	  (15)	  	  	  	  	  	  IIIB	   3	  (9)	  
Histology	  –	  no.	  (%)	   	  	  	  	  	  	  Squamous	  cell	  carcinoma	   25	  (73)	  	  	  	  	  	  Adenocarcinoma	   4	  (12)	  	  	  	  	  	  Adenosquamous	  carcinoma	   1	  (3)	  	  	  	  	  	  Glassy	  cell	  carcinoma	   4	  (12)	  
Treatment	  –	  no.	  (%)	   	  	  	  	  Preop	  brachytherapy	  +	  surgery	   5	  (15)	  	  	  	  Preop	  brachytherapy	  +	  surgery	  +	  EBRT	  +	  chemo	   8	  (23)	  	  	  	  Preop	  brachytherapy	  +	  surgery	  +	  EBRT	   5	  (15)	  	  	  	  Surgery	  +	  EBRT	  +	  chemo	  (+	  brachytherapy)	   6	  (18)	  	  	  	  Surgery	  +	  EBRT	  (+	  brachytherapy)	   1	  (3)	  	  	  	  Primary	  radiochemotherapy	  (+	  brachytherapy)	   9	  (26)	  
 
Abbreviations: EBRT, external beam radiotherapy;  
chemo, concomitant chemotherapy 
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Table 5. Characteristics of cervical cancer survivor and control women. 
Clinical variables Cervical cancer 
survivors 
N=34 
Control women 
 
N=37 
Age at time of study, mean (range) 41 (29-51) 40 (30-49) 
Age – no. (%)   
     <30 2 (6) - 
     30-34 3 (9) 6 (16) 
     35-39 8 (24) 8 (22) 
     40-44 11 (32) 15 (40) 
     45-50 9 (26) 8 (22) 
     >50 1 (3) - 
Marital status – no. (%)   
     Married or living with a partner 22 (65) 26 (70) 
     Has a partner but lives alone 1 (3) 3 (8) 
     Occasional partner 2 (6) 1 (3) 
     Single with no partner 9 (26) 6 (16) 
     Not stated - 1 (3) 
Menstrual cycle – no. (%)   
     Regular - 23 (62) 
     Irregular - 11 (30) 
     Not stated - 3 (8) 
Ongoing oral contraceptive – no. (%) - 14 (38) 
     Combined - 3 (8) 
     Gestagen - 11 (30) 
Local hormonal therapy – no. (%)  13 (38) - 
     Start at end of treatment 4 (12) - 
     Start at first follow-up 1 (3) - 
     Start when symptoms occurred 8 (23) - 
Systemic hormonal therapy – no. (%) 27 (79) - 
     Estrogen 23 (67) - 
     Combined 4 (12) - 
     Start at end of treatment 19 (56) - 
     Start at first follow-up 8 (34) - 
     Start when symptoms occurred 3 (9) - 
Systemic and local hormonal therapy – no. (%) 9 (26) - 
Vaginal dilator – no. (%) 19 (56) - 
     Started at end of treatment 10 (29) - 
     Started at first follow up 6 (18) - 
     Started when symptoms occurred 3 (9) - 
 
3.2 METHODS 
3.2.1 Tissue sampling (papers I-III) 
 
Vaginal biopsies were analyzed in study I-III. After a five-minute application of 
lidocaine/prilocaine cream (EMLA®, AstraZeneca, Sweden) two vaginal biopsies were 
taken from all the participants. The biopsies were taken with a 3 mm forceps at the three 
and nine o’clock positions, 3-4 cm proximal of the vaginal introitus. One biopsy was 
preserved in RNAlater (Thermo Fisher Scientific Life Sciences, Waltham, MA) for further 
RNA isolation. The second biopsy was placed in phosphate buffered 4 % formaldehyde 
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solution for approximately 12 hrs. Paraffin embedding was performed according to a 
standard protocol. The samples were cut vertical to the surface, with a nominal thickness of 
5 µm and mounted on slides. All biopsies and sections were handled and analyzed in a 
blinded manner throughout all analyses.  
3.2.2 Clinical assessments (papers I-II) 
 
One gynecological oncologist performed all the gynecological examinations in the cervical 
cancer survivors at a research visit. During the inspection, vaginal atrophy and the existence 
and quantification of telangiectasia were assessed. Atrophy was graded as absent (normal 
mucosa), mild (slightly pale mucosa, reduced folding), moderate (moderately pale, reduced 
folding) or severe (pronounced pallor, absent folding). Telangiectasia were scored as none 
(grade 0), single telangiectasia (grade 1), grouped telangiectasia (grade 2) and multiple 
telangiectasia (grade 3). Pelvic fibrosis and grade of vaginal inelasticity were determined by 
palpation as absent, mild (restricted to vagina), moderate (vagina and parametria) or severe 
(vagina and pelvis; “frozen pelvis”), Table 6. A vaginal measuring cylinder was used for 
measuring the vaginal length. One gynecologist examined all the control women according 
to protocol.  
 
Table 6. Grading system for vaginal parameters. 
 
3.2.3 Radiation dose at biopsy site (papers I-III) 
 
The cervical cancer survivors were treated before the use of 3D-guided BT. The EBRT 
plans were stored in an old planning system, from where the plans could not be retrieved. 
We therefore collected the prescribed field margins, target definition, set-up images, portal 
image films, treatment protocol and dose per fraction and the total prescribed dose for each 
patient. On portal image films the vaginal introitus was identified. The distance from the 
lower border of the EBRT field was measured and the EBRT dose at the biopsy site was 
calculated. For the BT we used orthogonal x-ray images and made an estimation of the 
delivered dose based on isodose-curves from the actual treatment for each patient. We 
calculated the EQD2 doses for both the EBRT and the BT, obtaining the total dose at the 
biopsy site. In order to correlate radiotherapy-induced histological findings, the radiation 
dose at the biopsy site was calculated in two different treatment groups; (I) pre-operative 
BT, (II) BT + EBRT + surgery or primary radiochemotherapy. 
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3.2.4 Blood sampling and analyses (papers II-III) 
 
Blood samples from the cervical cancer survivors were taken at the research visit. In the 
control women, blood samples were taken at the day of surgery. Serum estradiol, 
progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone 
and sex hormone-binding globulin (SHBG) were determined. The serum levels of estradiol 
and testosterone were determined by radioimmunoassay (RIA), Spectria, Orion 
Diagnostica. The serum levels of progesterone, FSH, LH, SHBG were determined by 
chemiluminescent immunometric assay, Immulite, Siemens. Details of the hormone assays 
are presented in Table 7. Free testosterone was determined by a formula using total 
testosterone, SHBG and a fixed concentration of albumin (40g/L) [198]. 
 
Table 7.  Hormone assays used in study II-III 
 
Abbreviations: CV, coefficient of variation; RIA, radioimmunoassay; ChLIA/CLIA, chemi-
luminescent immunometric assay; FSH, follicle-stimulating hormone; LH, luteinizing 
hormone; ND, not detectable; SHBG, sex hormone-binding globulin 
3.2.5 Measuring elastic fibers (paper I) 
 
The elastic fibers in the connective tissue were visualized by their autofluorescent 
properties in unstained sections in three images from each patient and control. The 
specimens were placed in the microscope (Axioplan 2, Zeiss) under a 40× objective and 
three random-sampled images per section were captured, with a 3-chip CCD RGB-color 
camera (Sony DXC-9100P). The images were digitized and stored in 8-bit RGB-mode in 
the computer under the control of MicroGOP 2000s (Context Vision) image-analysis 
software. The image size was equal in all specimens. Finally, the image-analysis program 
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calculated the area fraction of the elastic fibers (in percent) in each slide by dividing the 
total elastic fiber area by the total tissue area of the three images [199]. 
3.2.6 Measuring collagen content (paper I) 
 
To analyze the collagen content in the tissue, sections were stained with Sirius red, which 
binds covalently to the collagen molecule and is thus highly specific. Thereafter, the density 
of the collagen fibers was measured by intensitometry, i.e. calculation of the intensity of 
light passing through the collagen in the sections using the same equipment as above, but 
programmed for intensitometric measurements. The specimens were placed on a light table 
and the light was calibrated with a filter set of known densities. Optical density was 
estimated by detecting and measuring the area fraction for pixels in the specimen within 
certain defined grey level intervals, ranging from black = 0, to white = 255 (8-bit grey 
level). Subsequently, the total intensity, obtained from each grey level interval, was 
compared with the total area of the section [200, 201]. The collagen fibers were divided 
into four different panels (A-D) according to their optical densities; panel A representing 
the fibers with the highest density and panel D the fibers with the lowest density. For each 
participant three sections were evaluated and the result is presented as median percentage of 
total pixel area.  
3.2.7 Epithelial measurements (paper II) 
 
For capturing the complex structure of the vaginal epithelium with the dermal papilla, a 
computer-assisted method analyzed the epithelial structures [12]. The epithelial thickness, 
the number and the form of the dermal papillae, as well as and the dermal papillae distance 
were measured in µm. The following epithelial parameters were analyzed; the distance 
from dermal papilla top to epithelial surface (DPS), interdermal papilla distance (DPD), the 
dermal papilla width (DPW), the distance from basal layer to the epithelial surface (BLS) 
and the number of dermal papillae (Figure 7). In the microscope (Axioplan 2, Carl Zeiss, 
Jena, Germany) the specimens were placed under a 5x-objective and the specimen’s image 
was captured in 8-bit RGB-mode into the computer (Sun SparcStation 20, Sun 
Microsystems Computer Corp., CA) equipped with Micro-GOP 2000s (Context Vision, 
Linköping, Sweden) image analysis software. The threshold on the basal layer was set 
manually, thereafter the epithelial profile was outlined and the measurement procedure 
begun with the described parameters [12]. Each sample was analyzed from the left side to 
the right with five equally separated intervals of 411 µm each. 
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Figure 7. Epithelial parameters measured in each sample 
Abbreviations: DPS, distance from dermal papilla top to epithelial surface; DPD, 
interdermal papilla distance; DPW, dermal papilla width; BLS, distance from basal layer to 
epithelial surface. 
3.2.8 Blood vessels (paper II) 
 
To analyze the presence of blood vessels, sections were immunohistochemically stained 
with antibodies against coagulation factor VIII von Willebrand, present in endothelial cells 
[202]. The samples were placed in the microscope (Axioplan 2, Carl Zeiss, Jena, Germany) 
under the 20✕ objective and images were captured and digitally stored. Three grey scale 
pictures were made and then further enhanced with a stretch filtering and two contextual 
image procedures. The resulting picture was thresholded, presenting an accurate image of 
the vessels. Subsequently, a stereological cycloid grid was put on the image and the 
intercept points, where the grid touching the vessel wall, were identified (Figure 8). The 
program calculated the intercept points; six intercept measurements on each biopsy and the 
morphometrical analyses of blood vessels were made, by measuring the vessel surface area 
per unit tissue volume (mm2/mm3) [203, 204].  
 
 
 
Figure 8. Vaginal wall specimen stained with antibodies against coagulation factor VIII, 
with red cycloid measurement grid and green identifications marks at the vessel walls.  
Bar = 100 µm. 
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3.2.9 Nerve fibers (paper II) 
 
The specimens were also stained with antibodies against protein gene product 9.5 (PGP 
9.5), for the detection of nerve fibers (Figure 9) [6]. The volume fraction of IHC stained 
nerves was estimated in percent of the volume of examined tissue [201]. 
 
 
 
Figure 9. A specimen from the vaginal wall staid with antibodies against protein gene 
product 9.5 for detecting nerve fibers, with a grid showing red identifications marks at the 
nerve fibers. Bar = 100 µm. 
3.2.10 Questionnaire (paper II) 
 
The questionnaire was developed from a study-specific questionnaire, described and used 
by Bergmark et al, 1999 [143].  The original questionnaire was based on in-depth 
interviews with cervical cancer survivors, and face-to-face validated with cervical cancer 
survivors and women without a history of cancer treatment. In our questionnaire, we 
included 49 questions concerning demographic data, information on quality of life, 
psychological health and assessment of sexual dysfunction. Thirty-nine questions were 
specifically related to sexuality, such as sexual interest, vaginal lubrication and genital 
swelling, vaginal length reduction and inelasticity, superficial and deep dyspareunia and 
frequency of intercourse and orgasm.  
 
For questions on quality of life and psychological health a seven-point Visual Digital scale 
was used. Study persons were asked to estimate their wellbeing the last six months and 
responses on the scale ranging from 1-5 were considered as low to moderate and 6-7 as 
high. For responses on levels of anxiety and depression, 1-2 were considered absent or low 
and 3-7 moderate to high [205]. 
 
The specific questions on sexuality were covering overall sexual function, intercourse 
function and specific physical sexual symptoms like lubrication, vaginal elasticity and 
reduction in vaginal length. The answers were given in four to seven verbal categories, or 
that the symptom was not relevant. 
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For example;  
In some women, the elasticity of the vagina could feel reduced during sexual intercourse.  
 
Have you noticed that symptom during the last 6 months? 
☐ Not relevant - I have not engaged in sexual intercourse (or similar activity) during the 
last 6 months 
☐	 No,	  not	  at	  all 
☐	 Yes,	  a	  little	  reduced	  elasticity	  
☐	 Yes,	  moderately	  reduced	  elasticity	 
☐	 Yes,	  very	  reduced	  elasticity 
3.2.11 RNA preparation and reverse transcription (paper III) 
 
Total RNA from vaginal biopsies were purified with RNeasy® Mini Kit (Qiagen GmbH, 
Hilden, Germany) according the procedure for fibrous tissue recommended by the 
manufacturer. Two µg of total RNA from each sample was reverse transcribed at 37°C for 
60 min in a final volume of 40 µL. 
3.2.12 Real-time PCR analysis (paper III) 
 
For mRNA analyses of ERα, ERβ, G-protein-coupled ER-1 (GPER), PRA, PRB, AR, 
connective tissue growth factor (CTGF) and RPLP0 (ribosomal protein P0; a housekeeping 
gene) real-time PCR was performed in an iCycler™ iQ Real Time PCR System (Bio-Rad 
Laboratories, Inc, CA USA). The cDNAs, corresponding to 50–100 ng RNA, were added to 
12.5 µL of iQ™ SYBR® Green Supermix (Bio-Rad) and 0.3 µM of each oligonucleotide 
primer in a final volume of 25 µL PCR reactions. 
 
All reactions were performed in duplicates. A melting curve analysis was performed in all 
experiments to confirm the purity of the PCR products. Details on the used oligonucleotide 
primers are presented in Supplemental Table 1, paper III. All primers, except PRB, were 
designed to span an intron/exon boundary or to be on different exons, to eliminate 
amplification of contaminating DNA. A negative control containing a RNA sample without 
reverse transcription was included in each PCR assay. The mRNAs for PRA and PRB are 
transcribed from same gene, PRB mRNA being longer than PRA mRNA, why it is not 
possible to design primers that will detect only PRA mRNA. The PRAB primers will detect 
both PRA and PRB mRNAs as they are directed to the common sequence of the mRNAs 
while the primer pair for PRB mRNA will detect a part of the PRB mRNA that is unique 
and not translated into PRA.  
 
To standardize the quantification method, RPLP0 was selected out of several tested 
housekeeping genes as an invariable internal control and used to standardize the 
quantification method. The PCR amplification rate and the cycle threshold (Ct) values were 
related to a standard curve using iCycler iQ Optical System Software (Bio-Rad). The values 
of relative expression of the genes of interest were normalized against the RPLP0 product. 
  33 
3.2.13 Immunohistochemistry (paper III) 
 
Tissue sections were deparaffinized in xylene, then rehydrated in graded ethanol and 
microwaved for antigen retrieval in sodium citrate buffer for 10 min. Non-specific 
endogenous peroxidase activity was blocked by 3 % hydrogen peroxide in methanol for 10 
min at room temperature after a wash in buffer. Sections were exposed to normal horse or 
swine serum for 30 min. Thereafter the tissue sections were incubated with the primary 
antibody. Negative controls were obtained by replacing the primary antibody with the 
specie relevant IgG. The bound enzyme was visualized by the application of 3,3´-
diaminobenzidine after the incubation with horseradish peroxidase-avidin biotin complex. 
Counterstaining with haematoxylin and dehydration was performed before mounted with 
Pertex®. Details on dilutions, buffers and incubation times for the different antibodies are 
shown in Supplemental Table 2, paper III.  
3.2.14 Image analysis (paper III) 
 
To quantitatively assess nuclear immunostaining, a Leica microscope was connected to a 
computer using Colorvision software (Leica Imaging System Ltd. Cambridge UK). Ten 
fields were selected at random from the squamous epithelium and the stroma, for 
quantification of the area of positively immunostained (brown) nuclei. Analyzes were done 
separately for the two tissue types. When it was not possible to obtain ten separate fields 
due to lack of representative tissue, all epithelium and/or stroma was measured in those 
tissue samples. The total area of positively stained nuclei was determined and expressed as 
a ratio of the total area of cell nuclei (brown reaction product + blue haematoxylin) by the 
Colorvision software. This method was used for analyzing the nuclear receptors ERα, ERβ, 
PRA, PRB and AR. 
3.2.15 Manual scoring (paper III) 
 
GPER and CTGF immunostaining was measured by manual scoring due to their mainly 
cytoplasmic staining. Two independent observers scored, blinded for the identity of the 
samples, on a four-point scale from negative (0), (+) faint, (++) moderate and (+++) strong 
immunostaining. This method shows good consistency between two independent observers 
[206]. 
3.3 STATISTICS 
 
Data was analyzed using IBM SPSS Statistics 22.0 and SAS statistical software package. 
The analysis of data from the survivors and controls were performed using Student’s t-test 
or Mann-Whitney U-test wherever appropriate. Fisher’s exact test was used for comparing 
categorical variables between patients and controls. Analysis was performed by ANOVA 
on ranks (Kruskal-Wallis test) for comparing differences in more than two treatment groups 
and significances were evaluated by Dunn’s test all compared to all.  
 
Pearson correlation coefficient R was used to test correlation between hormonal levels and 
epithelial measurements variables. Spearman’s rank correlation test was used for 
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correlating vaginal atrophy and the responses of the questionnaires to the epithelial 
measurements. 
 
The responses to the questionnaire were dichotomized, and the results were presented as 
relative risks (95 % confidence intervals), calculated as a proportion of the cancer survivors 
reported a particular problem divided by the proportion of the controls. 
  
The significance level was set at p<0.05. 
 
4 RESULTS 
4.1 CLINICAL FINDINGS (I-III) 
 
The cervical cancer survivors had a shorter vagina, median 7.0 cm (range 5.0-9.0), 
compared to the control women, median 10.3 (7.0-13.0), p < 0.001. Clinical findings of 
atrophy, telangiectasia and pelvic fibrosis were commonly observed in different degrees in 
the cancer survivors (Table 8). 
 
Table 8. Clinical findings of cervical cancer survivor and control women. 
 Cervical cancer 
survivors 
N=34 
Control women 
  
N=37 
Length of vagina (cm), median (min-max) 7.0*(5.0-9.0) 10.3 (7.0-13.0) 
Length of vagina (cm) – no.    
     <6 3/34 0 
     6-7.9 22/34 1/37 
     8.0-9.9 9/34 9/37 
     >10 0 27/37 
Vaginal atrophy – no. (%) 31 (91) 0 
     No signs 3 (9) 37 (100) 
     Mild 15 (44) - 
     Moderate 15 (44) - 
     Severe 1 (3) - 
Telangiectasia – no. (%) 28 (82) 0 
     None 6 (18) 37 (100) 
     Mild 16 (47) - 
     Moderate 11 (32) - 
     Severe 1 (3) - 
Pelvic fibrosis – no. (%) 33 (97) 0 (0) 
     No signs 1 (3) 37 (100) 
     Mild 16 (47) - 
     Moderate 14 (41) - 
     Severe 3 (9) - 
 
*p<0.001 
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4.2 RADIATION DOSE AT BIOPSY SITE (I-III) 
 
Treatment with preoperative BT and radical surgery showed minimal dose at biopsy site, 
median 0.0 Gy (range 0.0-9.0). Five out of the 34 patients were cured with this treatment 
modality. Patients that received additional EBRT postoperatively and patients treated with 
primary radiochemotherapy received high dose at biopsy site; median 44.3 Gy (38.8-49.3) 
for postoperative EBRT and 53.4 Gy (47.9-69.0) for primary radiochemotherapy.  
 
In the further analyses the cervical cancer survivors were divided into two treatments 
groups. Group I were women treated with preoperative BT and surgery (n=5), receiving 
minimal radiation dose at the biopsy site, and group II were women that had received 
EBRT and high radiation dose at biopsy site (n=29). 
4.3 HORMONAL ANALYSIS (II-III) 
 
Serum estradiol was corresponding on a group level in cervical cancer survivors and control 
women. The median serum estradiol was 140.8 pmol/L (IQR 83.7-203.8) in the cervical 
cancer survivors, compared to 189.4 pmol/L (72.9-337.0), ns, in controls. The cervical 
cancer survivors in the two treatments groups, with minimal and high radiation dose at 
biopsy site (group I and II), also had corresponding levels of serum estradiol. Serum 
estradiol was median 108 pmol/L (IQR 59.0-147.0) in the women with minimal dose at 
biopsy site (n=5), compared to 145 pmol/L (85.0-208), ns, in the patients with high 
radiation dose at biopsy site (n=29). 
 
As expected, hormonal treatment with estradiol affected the serum level of estradiol. 
Cervical cancer survivors treated with both systemic and local estradiol (n=9) had 
significantly higher level of serum estradiol, median 185.2 pmol/L (IQR 123.0-257.2), 
compared to women with only local estradiol (n=4), median 25.3 pmol/L (8.0-100.3) or no 
hormonal therapy (n=3), 20.7 pmol/L (17.4-24.0), p=0.002. Cervical cancer survivors 
treated with only systemic estradiol (n=18) had median 144.1 pmol/L (106.2-208.6), no 
significant difference compared to the other hormonal treatments.  
 
Serum levels of estradiol in the control women were affected by the use of contraceptives. 
In control women using contraceptives (n=14), the serum estradiol was as anticipated low 
with median 80.4 pmol/L (IQR 33.6-206.1), compared to 218.6 pmol/L (83.2-455.4) in 
controls in the follicular phase (n=14) and 283.2 pmol/L (33.6-206.1) in controls in the 
luteal phase (n=8), p=0.022. 
 
Due to their history of cancer treatment, serum progesterone level was significantly lower 
and FSH and LH levels were higher in the cervical cancer survivors, compared to the 
control women. 
 
The SHBG level was higher in the cervical cancer survivors, median 77.7 nmol/L (IQR 
50.5-108.0), compared to 49.5 nmol/L (34.0-71.0) in the control women, p=0.003, but no 
significant differences were found between various groups concerning hormonal treatment. 
No significant differences were found in serum levels of testosterone. 
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4.4 HISTOLOGICAL FINDINGS 
4.4.1 Elastin (I) 
 
In the cervical cancer survivors, the area fraction of elastin in the vaginal wall was greater, 
10.0 % (range 0.8-18.1), compared to the control women 3.4 % (0.9-11.6), p<0.001. There 
was a marked difference in the organization and distribution of the elastic fibers (Figure 
10). In the control women, the elastin fibers were situated in a thin layer under the basal 
membrane of the epithelium. In the cervical cancer survivors, the elastin fibers were 
thickened and were located throughout the connective tissue forming a disorganized 
pattern. 
 
 
 
Figure 10. Autofluorescent elastin fibers in a sub-epithelial layer in the vaginal wall in 
control women (A), and thick elastin fibers in the connective tissue in cervical cancer 
survivors (B). Bar = 200 µm. 
4.4.2 Collagen (I) 
 
Collagen fibers were found in all the samples from the vaginal wall, but the distribution of 
fibers with different densities varied between the cervical cancer survivors and the control 
women. The collagen with the highest density (panel A) was most common in the cervical 
cancer survivors, median 43.7 % (range 1.1-84.2), compared to the controls, median 24.6 % 
(2.3-68.2), p<0.001. In the control women collagen fibers with the different densities were 
rather equally distributed. Cervical cancer survivors treated with EBRT (high radiation dose 
at biopsy site) had more collagen with the highest density, median 53.9 % (range 8.7-84.2), 
compared to the cancer survivors with minimal radiation dose at biopsy site 27.0 % (1.1-
36.4), p<0.01. 
4.4.3 Epithelial measurements (II) 
 
In the computer-assisted epithelial measurements the cervical cancer survivors had a 
thinner epithelium with a shorter distance from the basal layer to the epithelial surface 
(BLS), median 339 µm (IQ range 220-419), compared to 382 µm (IQ range 317-464) in the 
control women, p<0.05. As a further sign of a reduced epithelial volume, the distance 
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between the dermal papillae (DPD) was longer in the biopsies from the cervical cancer 
survivors, median 381 µm (IQ range 293-1002) compared to 279 µm (IQ range 239-337) in 
the controls, p<0.001. Consequently, the number of the normal papillae was lower in the 
specimen from the cervical cancer survivors, median 3.3 (IQ range 1.0-4.3), as compared to 
controls, 4.0 (IQ range 3.0-4.8), p<0.05. No differences in the distance from dermal papilla 
top to epithelial surface (DPS) or dermal papilla width (DPW) between survivors and 
control women were found (Figure 11).  
 
There were no differences in any of the epithelial measurements between patients with 
minimal radiation dose at the biopsy site (preoperatively BT only), compared to those who 
had received a high radiation dose (EBRT + BT). 
 
 
 
Figure 11. An illustration of the vaginal wall with the epithelial measurements in control 
women (A), and cervical cancer survivors with thinner epithelium (shorter BLS) and a 
longer distance between the dermal papilla (DPD) (B). *p<0.05 
Abbreviations: DPS, distance from dermal papilla top to epithelial surface; DPD, 
interdermal papilla distance; DPW, dermal papilla width; BLS, distance from basal layer to 
epithelial surface. 
4.4.4 Blood vessels (II) 
 
There was no difference in the mean surface area fraction of blood vessels per tissue 
volume in the vaginal wall in the cervical cancer survivors, compared to the control 
women. In the cancer survivors, the mean area fraction of blood vessels per tissue volume 
was 106.2 mm2/mm3 (SD 26.6), compared to the controls 101.6 mm2/mm3 (SD 25.6), ns. 
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4.4.5 Nerve fibers (II) 
 
There was a low volume fraction of nerves in the specimen from the vaginal wall from both 
cervical cancer survivors and control women, with no significant differences. The nerve 
tissue had a maximum of 1 % of the tissue volume in 75 % of the specimens; in the other 
25 % there were a maximum of 4 % nerve tissue. 
4.5 QUESTIONNAIRE (II) 
 
The cervical cancer survivors reported more vaginal sexual symptoms, compared to the 
control women. Among the cancer survivors, 39 %, compared to 3 % among the control 
women reported moderate or substantially insufficient vaginal lubrication for sex, relative 
risk (RR) 12.6, 95 % confidence interval (CI) 1.7-91.3. Accordingly, 36 % of the cancer 
survivors reported regular use of lubricants, compared to 3 % in the controls, RR 10.3 (95 
% CI 1.4-75.6). Almost half of the cancer survivors (45 %) reported moderate or 
substantially reduced elasticity of vagina, compared to 7 % of the controls, RR 6.5 (95 % 
CI 1.6-26.3). Also, the cancer survivors more often reported reduced genital swelling when 
sexually aroused and reduction in vaginal length during intercourse. No significant 
differences were seen in superficial and deep dyspareunia and the frequency of vaginal 
intercourse was similar in cancer survivors and control women.   
4.6 PCR (III) 
 
In the cervical cancer survivors (n=26), the relative mRNA expression of ERα in the 
vaginal wall was lower, median 0.5 (IQR 0.6-1.0), compared to the control women (n=29), 
median 0.8 (0.6-1.0), p=0.007. No differences in the relative mRNA expression of ERα 
were found between cervical cancer survivors treated with minimal radiation dose at biopsy 
site compared to the cancer survivors treated with high radiation dose at the biopsy site.  
Higher relative mRNA expression of CTGF was found in the cervical cancer survivors, 
median 0.6 (IQR 0.2-1.4), compared to controls median 0.2 (0.2-0.3), p=0.002. 
4.7 IMMUNOHISTOCHEMISTRY (III) 
 
In the vaginal biopsies, the ERα positive cells were mostly distributed along the basal 
membrane of the epithelium in both cervical cancer survivors and control women, and less 
frequently seen in the stroma. There was a lower immunostaining of ERα in the vaginal 
epithelium of the cervical cancer survivors (n=34), median 58.9 % (IQR 42.1-72.8), 
compared to controls (n=37), median 73.9 % (64.2-79.5), p=0.001. No significant 
differences were seen in the stroma (Figure 12). Further, when comparing the cervical 
cancer survivors that had received minimal or high radiation dose at biopsy site, there was a 
lower immunostaining of ERα in cancer survivors with high radiation dose (n=29), median 
56.8 % (37.3-69.9), compared to cancer survivors with minimal radiation dose at biopsy 
site (n=5), 75.2 % (61.7-84.0), p=0.046. The latter group showed values similar to the 
control women. Also, the amount of ERα positive cells in the stroma was lower in cancer 
survivors with high radiation dose, compared to cancer survivors with minimal radiation 
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dose at biopsy site. No significant differences were found concerning immunostaining of 
ERβ and GPER. 
 
 
 
Figure 12. Images of immunostaining of ERα in the vaginal wall in women treated for 
cervical cancer (A) and control women (B). Bar = 30 µm. 
 
The AR expressing cells were found both in the stroma and the epithelium. The cervical 
cancer survivors had a lower expression of AR in the epithelium, median 32.3 % (IQR17.4-
51.6), compared to 68.6 % (61.4-80.3) in the control women, p<0.001, but no difference in 
the stroma. Thereafter, when comparing the cancer survivors according to radiation dose at 
biopsy site, we found a lower immunostaining of AR in cancer survivors with high 
radiation dose, median 31.1 % (13.8-46.8), compared to cancer survivors with minimal 
radiation dose at biopsy site, 56.4 % (44.2-63.5), p=0.01. Also, the amount of AR positive 
cells in the stroma was lower in cancer survivors with high radiation dose, compared to 
cancer survivors with minimal radiation dose at biopsy site. 
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5 DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
 
Validity refers to the level of which the tests in a study are measuring what it is supposed to 
measure and the reliability the consistency of the measurement. Our clinical studies are 
limited according to the small sample size, but we aimed for good internal validity by 
minimizing systemic errors through a proper study design. 
 
Selection bias  
 
Selection bias can occur when the study population’s likelihood of participating in the study 
leads to a different result than we would have received if the whole target population were 
enrolled. Of the 66 cervical cancer survivors meeting the inclusion criteria and receiving a 
letter explaining the study, only 34 agreed to participate. There were no significant 
differences according to age, tumor stage and treatment modalities between participants and 
non-participants. The remaining 32 women most commonly referred to psychological 
reasons for not participating or the inconvenience of an extra visit at the clinic. The women 
who chose to participate could theoretically have more sexual symptoms than non-
participants, and therefore be more interested in the study. On the other hand, non-
participants could be women with more symptoms and discomfort during gynecological 
examination, thus denying participation. This could have biased our results regarding 
vaginal changes and sexual functioning towards worse or better. 
 
The control women were all scheduled for benign gynecological surgery. The reason for 
surgery varied from diagnosis of myoma, cervical dysplasia and endometriosis, to 
procedures of non-pathological origin, such as changing of IUD and sterilization. It is 
reasonable to believe that these control women had more sexual symptoms than a cross 
section of age-matched women from the general population, biasing the results concerning 
sexual function towards worse. So, the differences in sexual function could have been even 
larger if the premenopausal control women were selected randomly from the general 
population. We have no basis to believe that the vaginal histological changes could be 
biased by the fact that these women needed benign gynecological surgery. 
 
Information bias 
 
Information bias is caused if the data, collected in the study, is incorrect. Information bias is 
divided into differential and non-differential misclassification. Differential 
misclassification, non-random, could have occurred in study II when the cervical cancer 
survivors answered the questionnaire on sexual dysfunction. The cancer survivors were 
informed of the study objectives in advance. This fact could have made these women more 
aware of general symptoms and symptoms of sexual dysfunction, compared to the control 
women, who received the information of the study the same day as they participated and 
filled out the questionnaire.  
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Non-differential misclassification is caused by random measurement errors, which could 
have occurred in the hormonal and histological analyses. Random errors could weaken the 
outcome, causing null results even though an association is present. The hormonal analyses 
were performed in batches for minimizing random errors caused by assay variation. 
Another possibly source of random errors could have been the fact that the blood tests were 
taken at different time of the day and in the control women regardless of menstrual cycle. 
This could have diluted the results and made a wider distribution of values, but the positive 
associations found are therefore not believed to be caused by non-differential 
misclassification.  
 
The clinical findings and grading of vaginal atrophy, pelvic fibrosis and telangiectasia were 
performed by one gynecological oncologist in all cervical cancer survivors. A grading scale 
were established and evaluated by two observers before the start of the study. Vaginal 
length was measured by a vaginal measuring cylinder in the same manner in all study 
women. The vaginal biopsies in the cancer survivors were taken after a five-minute 
application of lidocaine/prilocaine cream with a 3 mm forceps. Punch biopsies would have 
been preferred for optimal histological analysis, but was not possible to use due to the 
vaginal biopsy sites. The vagina in the cancer survivors is typically narrowed and with 
reduced rugae, which complicates the taking of biopsies. In the control women, the biopsies 
were easier to take and the risk for mechanical damage of the biopsies were less. Some 
control women were under general anesthesia when the biopsy was taken. Even so, 
lidocaine/prilocaine cream was used in the same way, to minimize the risk of differences 
between groups due to the effect of the cream. 
 
The cervical cancer survivors in the studies were treated before modern radiotherapy 
modality with IMRT and 3D-guided BT was introduced. The radiation-dose at biopsy site 
was estimated by the information from the planning system and X-ray images by the same 
observers in each patient.  
 
Concerning the histological analysis for elastin and collagen the methods were chosen 
based on the knowledge and experience in the research group. The methods are simple and 
robust and based on proven stereological concepts. Elastin is a large and long molecule that 
is very difficult to solve and can therefore not be chemically quantified. For this reason, 
histological morphometric methods are much better suited. The fact that the elastin 
molecule is large causes it to autofluoresce. Unstained sections could therefore be used, 
reducing the risk of staining artifacts. Since we do not have a well-defined reference 
volume, the amount of elastin was specified as an area fraction, not a volume fraction. 
Three different images from each sample were then analyzed for a more reliable result.  
 
Collagen fibers exist in a large amount in the study biopsies. In fact, most of the connective 
tissue consists of collagen. For this reason, we used intensitometry to calculate the light 
passing through the sections, which not only investigate the amount of collagen but also the 
density of the collagen fibers. Sirius red was used to stain the collagen, known for being 
specific and stable [207]. Three different sections were analyzed from each study 
participant.  
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In studies analyzing the morphology of the vaginal epithelium, different methods have been 
used. Most frequently the epithelial thickness has been analyzed as the length from the 
epithelial surface to the basal membrane. For a more accurate epithelial measurement a 
computerized, stereological method was used in study II. This method not only defines the 
epithelial thickness, but also measures the epithelial structures with details of the dermal 
papillae. 
  
We studied the presence of blood vessel and nerve fibers in the biopsies by using IHC. 
When analyzing blood vessels, we used a method measuring the surface area fraction of 
blood vessels per tissue volume. In a histological section the same blood vessel could be 
seen in different parts due to its winding appearance. By measuring the area fraction instead 
of just counting the vessels in the sections, we achieved a more accurate measurement of 
the presence of blood vessels. One limitation is that the biopsies were small and thereby 
only showing the epithelium and the superficial part of the connective tissue. Important 
unidentified changes in blood vessels and nerve fibers could be present in the deeper part of 
the vaginal wall. 
 
The steroid hormone expression was analyzed at both mRNA and protein levels, using real-
time PCR and IHC. By using both methods the findings are strengthen. In the PCR 
analyses, adequate quantity and quality of RNA could only be extracted in 26 out of 34 of 
the samples from the cancer survivors, compared to 29 out of the 37 samples from the 
control women. A similar loss was obtained in both groups resulting in a reduction of total 
sample size. This could have limited the possibility to find small differences between the 
study groups. IHC for validation of the steroid hormone expression at the protein level is a 
clinically commonly used method. The limitations are the risk of subjectivity assessing the 
slides and the risk that differences in staining weaken the results. To overcome this, the 
samples were handed in a blinded manner and two independent observers performed the 
manual scoring. In the smallest samples, when ten randomly selected fields from the 
epithelium and stroma were not possible to obtain, all epithelium and/or stroma were 
analyzed.  
 
Confounding 
 
A confounding factor is a variable that is an independent risk factor for the outcome and is 
associated with the exposure, but not an effect of the exposure. A confounding factor can 
both overrate and underrate a result. A potential confounding factor in the hormonal 
analyses and histological measurements of the vagina is age. Therefore, when the study 
design was set, we chose to limit the study population to women age ≤51 years. In study II 
and III, the hormonal levels and hormonal treatment could be potential confounding factors 
and we therefore collected these data. To adjust for hormonal levels correlation tests were 
performed. The heterogeneous material concerning hormonal treatments in the cancer 
survivors and menstrual cycle and contraceptives in the control women could have 
influence the results. This must be taken into account in the interpretation of the findings.  
 
Smoking is a potential confounding factor in the studies. We have no information on 
smoking habits from the control women, but in the cervical cancer survivors 11 out of 34 
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were smokers at the time of the study. Smoking habits could affect the radiotherapy-
induced fibrosis, but a larger study group would have been needed for adjusted data 
analysis. 
 
Confounding from comorbidity was controlled by restriction, as being one of the exclusion 
criteria in both cancer survivors and control women.  
5.2 MAIN FINDINGS AND IMPLICATIONS 
5.2.1 Clinical findings 
 
In the cervical cancer survivors, we found clinical signs of atrophy, pelvic fibrosis and 
telangiectasia, which was in contrast to the absence of these signs in the control women. 
The vaginal length was reduced in the cancer survivors, compared to control women. The 
cancer survivors that had received external pelvic radiation showed the most prominent 
changes in atrophy, pelvic fibrosis and vaginal length. These findings are in concordance 
with the observations on vaginal changes reported by Kirchheiner et al. [183]. 
5.2.2 Histological findings in the connective tissue 
 
In the vaginal connective tissue, we found fibrosis and high elastin content (elastosis) in 
cervical cancer survivors treated with radiotherapy. The most prominent fibrotic changes 
were found in the cancer survivors with high radiation dose at biopsy site, i.e. the women 
that had been treated with external pelvic radiation. To our surprise, we found a higher area 
fraction of elastin in the cancer survivors, compared to controls. However, when we studied 
the microscopic slides we found that the distribution and characteristics of the elastin fibers 
were changed. In the control women, the elastin fibers formed a thin sub-epithelial layer 
along the basal membrane, but in the cancer survivors, compact elastin fibers were spread 
throughout the connective tissue. These results together with the clinical finding of inelastic 
vaginal walls in the cancer survivors indicate that the elastin is dysfunctional. In the 
correlations analysis, we found no significant difference in elastin content in the cancer 
survivors with high radiation dose at biopsy site, compared to survivors that only received 
minimal radiation dose. This result might be due to the small sample size, with only five 
patients in the latter group. High prevalence of elastin in the connective tissue is seen in the 
connective tissue disease of scleroderma, which cause thicken, harder skin, with loss of 
elasticity [208]. The histological findings also have morphological similarities to actinic 
elastosis seen in sun-damaged skin [209].  
 
The collagen showed higher density in the cancer survivors compared to controls. The 
collagen with the highest density, i.e. fibrosis, were also more common in the cancer 
survivors that had received a high radiation dose at biopsy site, compared to the patients 
treated with preoperative BT and surgery and thereby only received minimal radiation dose 
at the distal part of the vagina. Consequently, we conclude that the fibrosis is radiotherapy-
induced. These connective tissue changes can alter the function of the vaginal wall and play 
an important role in a morphological explanation of the clinical findings and physical 
symptoms in cervical cancer survivors. 
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For a functional vaginal wall the blood vessels and nerve fibers are essential. We found no 
differences in the area fraction of superficial blood vessels and nerve fibers between cancer 
survivors and controls. In our biopsies only the upper part of the vaginal wall was 
represented, therefore possible deeper located changes important for the microcirculation of 
the tissue could not be studied. A clinical observation when taking the biopsies were that 
there was almost no bleeding in the cancer survivors, compared to the control women, 
where in a few cases even a stitch was needed for hemostasis. Photoplethysmography could 
be a better method for analyzing the vessel function in the vaginal wall [210]. 
5.2.3 Histological findings in the epithelium 
 
We found morphological changes in the cervical cancer survivors with reduced vaginal 
epithelial volume, compared to control women. The cancer survivors had a shorter distance 
from the basal layer to the epithelial surface and sparse dermal papillae, indicating not only 
a thinner epithelium but also a reduced epithelial volume and function. These 
morphological findings correlate to our clinical findings of atrophy. The dermal papillae 
contain blood vessels and are essential for the function of the avascular epithelium. A 
reduced number of dermal papillae can negatively influence the nourishment by the 
capillaries and further reduce the growth of the mucosa. To obtain effect of systemic 
estrogen, the hormone has to reach the receptors of the target cells. As expected, we found a 
positive correlation between serum levels of estradiol and the epithelial thickness when 
including all study participates. The cancer survivors were all treated with radiotherapy 
resulting in complete cessation of the endogen ovarian estrogen production. A majority of 
the cancer survivors were using systemic hormonal treatment and on a group level there 
was no difference in the serum estradiol, implying that the survivors were sufficiently 
substituted. Even so, vaginal atrophy was found both clinically and morphologically, 
supporting previous findings that radiotherapy affects the responsiveness to estrogen [186]. 
One may speculate if the reason for this could be the fibrotic changes in the connective 
tissue and the loss of dermal papillae with impact on the microcirculation and/or changes in 
the expression of hormone receptors. 
5.2.4 Hormonal levels 
 
The analyses of the serum hormonal levels showed postmenopausal values for FSH, LH 
and progesterone in the cervical cancer survivors, compared to the premenopausal control 
women. There was no difference in serum estradiol on a group level, between the cancer 
survivors and the control women. However, the material was heterogeneous concerning the 
hormone therapy, both regarding systemic and local estradiol treatment. This reflects the 
variation in clinical recommendations and compliance after the cervical cancer treatment is 
completed [211]. The estradiol levels varied, depending on the hormonal therapy, with the 
highest levels in the cancer survivors treated with both systemic and local estradiol, and the 
lowest levels in those with only local estradiol or no treatment at all. On the other hand, the 
control women with contraceptives showed as expected lower levels of estradiol compared 
to the cycling controls. In the cancer survivors, 79 % used systemic estradiol and a 
corresponding number of controls (62 %) were not using contraceptives, which explain the 
equal estradiol level between cancer survivors and controls. 
  45 
5.2.5 Sex steroid hormone receptors 
 
In the cervical cancer survivors, we found a lower expression of ERα in the vaginal wall at 
both mRNA and protein levels, compared to control women. The cancer survivors that had 
received external radiation as part of their treatment, with a high radiation dose at the 
vaginal biopsy site, showed lower expression of ERα in both epithelium and stroma, 
compared to the survivors treated with BT and surgery. To our knowledge, there are no 
previous studies on the steroid receptor expression in the vaginal wall after treatment of 
cervical cancer with radiotherapy. However, the dynamic interplay between the steroid 
hormone receptors and the serum hormone levels has been demonstrated in several studies 
in pre- and postmenopausal women with vaginal prolapse. A lower ERα expression in the 
vaginal wall has been found in postmenopausal women, compared to premenopausal 
women [114, 115], with increased expression in women treated with local estrogen [116], 
but less with systemic administration [122]. Our findings with lower ERα expression in a 
patient group were the majority were using hormonal therapy, might indicate that the 
vaginal mucosa is less likely to respond to estrogen therapy after radiation. At the same 
time, we must not forget that this finding applies to patients two to five years after the end 
of the cancer treatment, when the long-term side effects are considered permanent. Early 
start and accurate dosage of local estrogen therapy might preserve the mucosal 
responsiveness to estrogen.  
 
We also found a lower AR expression in the epithelium in the cancer survivors compared to 
control women. In the cancer survivors with high radiation dose at the biopsy site, the 
immunostaining of AR was lower in both epithelium and stroma, compared to survivors 
with minimal radiation dose. AR expression in the vaginal wall in women with no history 
of cancer, have shown higher expression in premenopausal, compared to postmenopausal 
women [121]. Even though the knowledge on the effects of AR and testosterone on the 
vagina is limited, studies on rabbits have shown AR involvement in the vaginal 
hemodynamics and vaginal mucification [212]. Changes in the AR expression could 
therefore have effects on the vaginal sexual response. 
 
CTGF is a central mediator of tissue remodeling and fibrosis [213]. Our finding of higher 
mRNA expression of CTGF in the vaginal wall in the cancer survivors, compared to 
controls, is in concordance with our previous results of radiotherapy-induced fibrosis in the 
connective tissue. Studies on mice have indicating that inhibition of CTGF can prevent and 
reverse the process of radio-induced pulmonary fibrosis [214]. 
5.2.6 Sexual function 
 
Sexual dysfunction in cervical cancer survivors is complex and has multifactorial etiology. 
Persistent changes in sexual function in cervical cancer survivors are reported and result in 
considerable distress [143]. We found that the cancer survivors reported more physical 
symptoms like reduced lubrication and elasticity, reduction in vaginal length and sexual 
response with genital swelling, compared to the control women. These symptoms could be 
mediated by the morphological changes in the vaginal wall. The reduction in length and 
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elasticity of the vagina is probably partly due to the radiotherapy-induced fibrosis, but also 
by the surgery in the patients where radical hysterectomy was part of the treatment [215].  
 
Lubrication and genital swelling during sexual arousal is dependent on increased blood 
flow, but the decreased epithelial volume and the changed connective tissue in the cancer 
survivors could also affect the ability to respond sexually. Dyspareunia is reported in 
several previous studies as one of the most distressing symptoms after cervical cancer 
treatment with radiotherapy [162]. We found no difference regarding dyspareunia between 
the cancer survivors and the control women. This might be due to the small sample size, but 
we must also take into consideration that the women in the control group were planned for 
gynecological surgery. The differences in sexual function could have been even larger if the 
control women were randomly selected from the general population. 
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6 GENERAL CONCLUSIONS 
• In cervical cancer survivors treated with radiotherapy, the connective tissue in the 
vaginal wall is changed, with development of fibrosis and elastosis. The highest risk 
of vaginal fibrosis is seen in women treated with external radiation. 
 
• Cervical cancer survivors treated with radiotherapy have a reduced vaginal epithelium 
volume and clinical signs of vaginal atrophy, compared to control women with 
corresponding serum levels of estradiol. 
 
• Irradiated cervical cancer survivors have an increased risk of vaginal sexual symtoms; 
such as insufficient lubrication, inelasticity, reduced genital swelling when sexually 
aroused and reduced vaginal length. 
 
• Cervical cancer survivors treated with external radiation have reduced ERα and AR 
expression in the vaginal mucosa. The vaginal atrophy after cervical cancer treatment 
could partly be due to decreases in sex steroid hormone receptor expression.  
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7 FUTURE PERSPECTIVES 
 
Cervical cancer survivors are a rising number of women at risk for chronic side effects. The 
improvements in treatment result in increased survival rates, but the advanced treatment 
must also induce minimal morbidity for reaching our goal to cure with the best possible 
quality of life. Sexual dysfunction is reported as one of the most distressful symptoms after 
the end of treatment, which point out the need for efforts to cure with minimal vaginal 
symptoms and maintained sexual health. Our studies serve as a step towards better 
knowledge of the morphological changes in the vaginal wall in cervical cancer survivors. 
 
Studies are required to evaluate therapy developments in radiotherapy and new surgical 
techniques in the treatment of cervical cancer. In the progress of modern radiotherapy, we 
need to gain more knowledge of the distribution of the vaginal radiation dose and thereby 
improving the individually treatment planning, minimizing the vaginal side effects. The 
relationship between vaginal dose and the risk for vaginal side effects needs to be evaluated 
in future studies. 
 
An intervention study is needed to evaluate the potential effect of local estrogen therapy in 
preventing vaginal morbidity and sexual dysfunction. The timing, dosage and 
administration form of the treatment ought to be studied in a large patient group with long-
term follow-ups. The optimal start of treatment is probably immediately upon completion 
of radiotherapy. Usually, the prescribed dosage of the topical estrogen is the same as for 
treating vaginal atrophy in postmenopausal women with no history of radiation. Higher 
doses and more frequent administration might be needed to reduce vaginal symptoms after 
radiation. The various applications of topical treatment, cream, gel or vaginal tablets, could 
also have different effects that needs to be further evaluated for more individualized 
guidance. 
 
The use of vaginal dilators is widely recommended in guidelines, but still the evidence is 
weak concerning long-term benefits [216]. The use of dilators during the radiotherapy is 
not supported. It has been suggested to start dilation once the acute inflammation has 
settled, but it is still unclear whether early use of dilators can prevent vaginal stenosis. It 
should be possible to set up a study protocol for a randomized controlled trial investigating 
optimal start, frequency and long-term effect. However, there are several issues to consider. 
In previous studies, it has been shown that women developing stenosis are more reluctant to 
continue with the dilators and for some women the use of dilators is stressful [217]. 
 
The benefit of other topical drugs, such as benzydamine (NSAID) and products containing 
A and E vitamins, as well as surgical reconstruction of the vagina, has been reported in 
minor studies [218-220], but further evaluation is needed.  
 
The heterogeneity in the cancer survivors in this thesis regarding hormonal treatment and 
use of vaginal dilator, demonstrate the need to strengthen the rehabilitation programs and 
strive towards a multi-professional organization. Information to the patients before, during 
and after the treatment can be further developed to improve the compliance. Current 
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clinical guidelines address the issue and give recommendations in the rehabilitation phase, 
but health-care providers must be organized and prepared to meet the requirements. 
 
Sexual symptoms can be difficult to address both for patients and professionals. Written 
information and clinically designed questionnaires can be helpful and give the patients a 
more standardized follow-up regarding sexual health. Studies on side effect prevention and 
information regarding sexual issues in women treated for gynecological cancer, may further 
improve the cancer survivors’ quality of life.  
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